<html><head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
</head><body>
<span style="position:absolute; border: gray 1px solid; left:0px; top:50px; width:585px; height:783px;"></span>
<div style="position:absolute; top:50px;"><a name="1">Page 1</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:87px; width:180px; height:8px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">1502 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">The Journal of Neuroscience, February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:135px; width:99px; height:12px;"><span style="font-family: ALPEDK+MinionMM-SemiBoldCondensed; font-size:12px">Neurobiology of Disease
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:162px; width:492px; height:74px;"><span style="font-family: ALPEDK+MinionMM-SemiBoldCondensed; font-size:24px">Blockade of Astrocytic Calcineurin/NFAT Signaling Helps to
<br>Normalize Hippocampal Synaptic Function and Plasticity in
<br>a Rat Model of Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:259px; width:493px; height:47px;"><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:12px">Jennifer L. Furman,</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:7px">1</span><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:12px">* Pradoldej Sompol,</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:7px">2</span><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:12px">* X Susan D. Kraner,</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:7px">2 </span><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:12px">Melanie M. Pleiss,</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:7px">1,2 </span><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:12px">Esther J. Putman,</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:7px">2
<br></span><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:12px">X Jacob Dunkerson,</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:7px">2 </span><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:12px">Hafiz Mohmmad Abdul,</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:7px">2 </span><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:12px">Kelly N. Roberts,</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:7px">2 </span><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:12px">Stephen W. Scheff,</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:7px">2,3 </span><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:12px">and Christopher M. Norris</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:7px">1,2
<br></span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:5px">1</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:9px">Department of Pharmacology and Nutritional Sciences, </span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:5px">2</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:9px">Sanders-Brown Center on Aging, and </span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:5px">3</span><span style="font-family: ALPEMP+MinionMM-RegularCondensed; font-size:9px">Department of Anatomy and Neurobiology, University of
<br>Kentucky College of Medicine, Lexington, Kentucky 40536
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:334px; width:501px; height:155px;"><span style="font-family: ALPEDK+MinionMM-SemiBoldCondensed; font-size:11px">Increasing evidence suggests that the calcineurin (CN)-dependent transcription factor NFAT (Nuclear Factor of Activated T cells) medi-
<br>ates deleterious effects of astrocytes in progressive neurodegenerative conditions. However, the impact of astrocytic CN/NFAT signaling
<br>on neural function/recovery after acute injury has not been investigated extensively. Using a controlled cortical impact (CCI) procedure
<br>in rats, we show that traumatic brain injury is associated with an increase in the activities of NFATs 1 and 4 in the hippocampus at 7 d after
<br>injury. NFAT4, but not NFAT1, exhibited extensive labeling in astrocytes and was found throughout the axon/dendrite layers of CA1 and
<br>the dentate gyrus. Blockade of the astrocytic CN/NFAT pathway in rats using adeno-associated virus (AAV) vectors expressing the
<br>astrocyte-specific promoter Gfa2 and the NFAT-inhibitory peptide VIVIT prevented the injury-related loss of basal CA1 synaptic strength
<br>and key synaptic proteins and reduced the susceptibility to induction of long-term depression. In conjunction with these seemingly
<br>beneficial effects, VIVIT treatment elicited a marked increase in the expression of the prosynaptogenic factor SPARCL1 (hevin), espe-
<br>cially in hippocampal tissue ipsilateral to the CCI injury. However, in contrast to previous work on Alzheimer’s mouse models, AAV-
<br>Gfa2-VIVIT had no effects on the levels of GFAP and Iba1, suggesting that synaptic benefits of VIVIT were not attributable to a reduction
<br>in glial activation per se. Together, the results implicate the astrocytic CN/NFAT4 pathway as a key mechanism for disrupting synaptic
<br>remodeling and homeostasis in the hippocampus after acute injury.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:496px; width:262px; height:11px;"><span style="font-family: ALPGAC+MinionMM-SemiBoldItalicCondensed; font-size:10px">Key words: </span><span style="font-family: ALPEDK+MinionMM-SemiBoldCondensed; font-size:11px">astrocytes; brain injury; calcineurin; calcium; glia; synapse
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:55px; top:537px; width:475px; height:111px;"><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:11px">Significance Statement
<br></span><span style="font-family: ALPEDK+MinionMM-SemiBoldCondensed; font-size:11px">Similar to microglia, astrocytes become strongly “activated” with neural damage and exhibit numerous morphologic/biochemical
<br>changes, including an increase in the expression/activity of the protein phosphatase calcineurin. Using adeno-associated virus
<br>(AAV) to inhibit the calcineurin-dependent activation of the transcription factor NFAT (Nuclear Factor of Activated T cells)
<br>selectively, we have shown that activated astrocytes contribute to neural dysfunction in animal models characterized by progres-
<br>sive/chronic neuropathology. Here, we show that the suppression of astrocytic calcineurin/NFATs helps to protect synaptic
<br>function and plasticity in an animal model in which pathology arises from a single traumatic brain injury. The findings suggest
<br>that at least some astrocyte functions impair recovery after trauma and may provide druggable targets for treating victims of acute
<br>nervous system injury.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:689px; width:243px; height:35px;"><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:13px">Introduction
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Astrocytes exhibit striking morphological changes with CNS in-
<br>jury and disease, which are collectively referred to as “astrocyte
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:741px; width:150px; height:7px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">Received May 19, 2015; revised Nov. 15, 2015; accepted Dec. 10, 2015.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:750px; width:243px; height:25px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">Author contributions: J.L.F., P.S., S.D.K., S.W.S., and C.M.N. designed research; J.L.F., P.S., S.D.K., M.M.P., E.J.P.,
<br>J.D., H.M.A., K.N.R., and C.M.N. performed research; J.L.F., P.S., S.D.K., S.W.S., and C.M.N. analyzed data; J.L.F., P.S.,
<br>S.D.K., and C.M.N. wrote the paper.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:777px; width:243px; height:25px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">This work was supported by grants the National Institutes of Health (Grant AG027297 to C.M.N., Grant AG000242
<br>to P.S., and Grant AG047762 to M.M.P.); the Kentucky Spinal Cord and Head Injury Research trust (Grant 12-10A to
<br>C.M.N. and Grant 12-16A to S.W.S.); the PhRMA Foundation (graduate fellowships to J.L.F. and M.M.P.); the Irene
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:690px; width:243px; height:54px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">activation” (Pekny and Nilsson, 2005; Parpura et al., 2012; An-
<br>derson et al., 2014). Hypertrophy of astrocyte somata and pro-
<br>cesses, along with a corresponding increase in the expression of
<br>the glial fibrillary acidic protein (GFAP), are the most robust and
<br>recognizable biomarkers of activated astrocytes, yet the func-
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:768px; width:243px; height:16px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">and Eric Simon Brain Research Foundation (undergraduate fellowship to E.J.P.); and the Hazel Embry Research Trust.
<br>We thank Linda Simmerman and Adam Bachstetter for technical assistance.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:786px; width:113px; height:16px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">The authors declare no competing financial interests.
<br>*J.L.F. and P.S. contributed equally to this work.
<br></span></div><span style="position:absolute; border: black 1px solid; left:43px; top:528px; width:500px; height:133px;"></span>
<div style="position:absolute; border: figure 1px solid; writing-mode:False; left:-9px; top:614px; width:369px; height:227px;"><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:224px; top:260px; width:8px; height:8px;"></div></div><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:-8px; top:602px; width:550px; height:239px;"><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:43px; top:272px; width:8px; height:8px;"></div></div><span style="position:absolute; border: gray 1px solid; left:0px; top:883px; width:585px; height:783px;"></span>
<div style="position:absolute; top:883px;"><a name="2">Page 2</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:917px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:403px; top:920px; width:140px; height:8px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">• 1503
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:945px; width:243px; height:98px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">tional phenotype of these cells appears highly complex. In intact
<br>animal models, targeted approaches for inhibiting GFAP expres-
<br>sion or for modulating the activity of major astrocytic signaling
<br>pathways have demonstrated both protective and deleterious
<br>roles of activated astrocytes in neural function depending on the
<br>nature of the injury (e.g., chronic neurodegeneration vs acute
<br>trauma) and the proximity of astrocytes to the site of injury/
<br>pathology, among many other factors (Sofroniew, 2009; Pekny
<br>and Pekna, 2014; Pekny et al., 2014; Burda et al., 2015).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:1044px; width:243px; height:362px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Several key morphologic and biochemical features of astro-
<br>cyte activation have been linked to the expression and/or
<br>the Ca </span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:6px">⫹</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">/calmodulin-dependent protein
<br>hyperactivation of
<br>phosphatase calcineurin (CN) (Norris et al., 2005; Fernandez et
<br>al., 2007; Canellada et al., 2008; Furman et al., 2012; Furman and
<br>Norris, 2014). Although weakly expressed in astrocytes in healthy
<br>adult nervous tissue, CN can appear at high levels in activated
<br>astrocytes associated with aging (Norris et al., 2005), acute injury
<br>(Hashimoto et al., 1998), and progressive amyloid pathology
<br>(Norris et al., 2005; Celsi et al., 2007; Abdul et al., 2009). In
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">peripheral tissues, including lymphoid tissue, heart, vascular
<br>smooth muscle cells, and skeletal muscle, CN is known to
<br>strongly regulate the morphological and functional phenotypes
<br>of cells through the activation of NFAT (Nuclear Factor of Acti-
<br>vated T cells) transcription factors (Crabtree and Olson, 2002;
<br>Horsley and Pavlath, 2002; Hogan et al., 2003; Wilkins and Molk-
<br>entin, 2004; Hassoun et al., 2009). There are four CN-dependent
<br>NFAT isoforms (i.e., NFATs 1– 4), all of which are expressed in
<br>mammalian brain (Nguyen and Di Giovanni, 2008; Vihma et al.,
<br>2008). Changes in NFAT expression/activity, especially for the
<br>NFAT1 and 4 isoforms, have been observed in astrocytes in pro-
<br>gressive neurodegenerative conditions such as Alzheimer’s dis-
<br>ease (AD) (Abdul et al., 2009) and Parkinson’s disease (Caraveo
<br>et al., 2014) and also after acute nervous system injury (Serrano-
<br>Pe´rez et al., 2011; Yan et al., 2014). Blockade of CN/NFAT inter-
<br>actions in astrocytes using adeno-associated virus (AAV) vectors
<br>and the CN docking site mimetic peptide VIVIT suppressed glial
<br>activation, reduced amyloid pathology, and improved synaptic
<br>function in a mouse model of AD (Furman et al., 2012), suggest-
<br>ing that astrocytic CN/NFAT signaling may be detrimental
<br>to neural function in chronic neurodegenerative conditions.
<br>Whether CN/NFAT plays a similarly deleterious role in activated
<br>astrocytes after acute neural injury is unknown.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:1407px; width:243px; height:153px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Here, we investigated the DNA-binding activities of all four
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">CN-dependent NFAT isoforms in rat hippocampus 7 d after a
<br>unilateral cortical contusion injury (CCI). Although we found
<br>evidence for increased expression of the NFAT1 and 4 isoforms,
<br>specific colocalization with GFAP-positive astrocytes was only
<br>observed for NFAT4. Intrahippocampal injection of AAV vectors
<br>containing the astrocyte-specific promoter Gfa2 and the NFAT
<br>inhibitory peptide VIVIT prevented the weakening of basal CA3–
<br>CA1 synaptic strength, reduced susceptibility to long-term syn-
<br>aptic depression (LTD), and protected against the loss of several
<br>key synaptic proteins. However, AAV-Gfa2-VIVIT did not ap-
<br>preciably alter astrocyte or microglial protein markers (i.e., GFAP
<br>and Iba-1, respectively). The results suggest that astrocytic CN/
<br>NFAT signaling can impair and/or prevent the recovery of syn-
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:1592px; width:243px; height:34px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">Correspondence should be addressed to Dr. Christopher M. Norris, Department of Pharmacology and Nutritional
<br>Sciences, University of Kentucky College of Medicine, 224 Sanders-Brown Building, 800 South Limestone St., Lex-
<br>ington, KY 40536. E-mail: cnorr2@uky.edu.
<br>DOI:10.1523/JNEUROSCI.1930-15.2016
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:1628px; width:64px; height:7px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">Copyright © 2016 the authors
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:112px; top:1628px; width:75px; height:7px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">0270-6474/16/361503-14$15.00/0
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:945px; width:243px; height:21px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">aptic function after traumatic brain injury without reducing
<br>astrocyte activation per se.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:972px; width:243px; height:244px;"><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:13px">Materials and Methods
<br></span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">Animals and TBI</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">. Adult (</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">2-month-old) male Sprague Dawley rats
<br>(250 –275 g; Harlan Laboratories) were housed 2/cage on a 12 h light/
<br>dark cycle, provided access to food and water </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">ad libitum</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">, and used in
<br>accordance with the Institutional Animal Care and Use Committee of the
<br>University of Kentucky. Stereotaxic surgeries and delivery of traumatic
<br>brain injury was performed with slight modifications of our previous
<br>methods (Norris and Scheff, 2009; Ansari et al., 2013; Scheff et al., 2013).
<br>Briefly, rats were anesthetized with 2% isofluorane and immobilized in a
<br>Kopf stereotaxic frame with the incisor bar set at </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫺</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">5. Body temperature
<br>for each rat was monitored and maintained at 36°C with a Space Gel
<br>heating pad (Braintree Scientific). After a midline incision and retraction
<br>of the skin, a 6-mm-diameter craniotomy was made lateral to midline
<br>and approximately midway between bregma and lambda with a Michele
<br>hand trephine and the skull disk was removed without disturbing the
<br>dura. An electronic controlled pneumatic impact device (TBI0310; Pre-
<br>cision System) with a hard stop Bimba cylinder was used to deliver a
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">moderate unilateral controlled cortical impact (CCI) injury, which com-
<br>pressed the cortex to a depth of 2.0 mm at a velocity of 3.5 m/s. After the
<br>injury, the craniotomy site was sealed with MASCOT adhesive (EMS)
<br>and an 8 mm disc formed from clear polyester (0.5 mm; Midwest Prod-
<br>ucts). In some cases, rats were subjected to craniotomy, but did not
<br>receive a CCI, and served as sham controls. The surgical procedure was
<br>completed in 15–20 min.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:1218px; width:243px; height:109px;"><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">Electrophoretic mobility shift assay. </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">As the EMSA probe, a duplex DNA
<br>oligonucleotide labeled on its 5</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬘ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">ends with IRDye 700 (LI-COR) was ob-
<br>tained from Integrated DNA Technologies. The sequence of the strands were
<br>(5</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬘</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">-IRDye700-ACAT</span><span style="font-family: ALPIJI+Minion-BoldItalic; font-size:9px">TGGAAAA</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">TTTTATTACACCA-3</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬘ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">annealed to 5</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬘</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">-
<br>IRDye700-TGGTGTAATAAAA</span><span style="font-family: ALPIJI+Minion-BoldItalic; font-size:9px">TTTTCCA</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">ATGT-3</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬘</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">) and corresponded to
<br>the NFAT binding site from the IL4 promoter, with which previous high-
<br>quality EMSAs have been performed by others (Neal and Clipstone, 2001).
<br>Probe specificity was assessed using an unlabeled wild-type competitor of the
<br>same sequence or a mutant competitor containing an altered NFAT-binding
<br>site (TGGAAAA</span><span style="font-family: ALPINJ+OurOwn-CJS; font-size:9px">¡ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">CTTTAAA). When indicated, these competitors were
<br>included at a 100-fold molar excess in the EMSA-binding mix.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:1328px; width:243px; height:309px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">Whole cell extracts from frozen brain tissue at 7 d after CCI were made
<br>using a kit from Active Motif following the manufacturer’s instructions
<br>and protein assays performed using a Bradford assay. The binding reac-
<br>tion used for these experiments contained 10 m</span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">M </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">Tris, pH 7.5, 50 m</span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">M
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">NaCl, 1 m</span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">M </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">EDTA, 1 m</span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">M </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">DTT, 0.05% NP40, 5% glycerol, 0.5 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">g of poly
<br>dIC, 5 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">g of BSA, 10% 10</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">orange loading buffer (LI-COR), 1% pro-
<br>tease inhibitor mixture III (EMD Millipore), and 1% phosphatase inhib-
<br>itor mixture II (EMD Millipore), indicated extract, and 10 femtomoles of
<br>IL4 NFAT probe. To induce supershift/blockshift with NFAT antibodies,
<br>3.3 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l of the indicated NFAT antibody was added to the mixture and 3.3
<br></span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l of PBS to the negative control. NFAT1 (Abcam, catalog #ab2272),
<br>NFAT2 (Santa Cruz Biotechnology, catalog #sc-13033x), NFAT3 (Santa
<br>Cruz Biotechnology, catalog #sc-13036x), and NFAT4 (Santa Cruz Bio-
<br>technology, catalog #sc-8405x) were used individually. For some condi-
<br>tions, NFAT1 and NFAT4 antibodies were used in combination, as
<br>indicated. EMSA samples were incubated on ice for 2 h, covered with
<br>foil to protect fluorescent probe from photobleaching, and incubated
<br>at room temperature for 10 min before loading on gels. Electropho-
<br>resis was performed on chilled 5% nondenaturing polyacrylamide
<br>gels in </span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">1</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">⁄</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">TBE running buffer in a cold room for 1 h and 50 min at
<br>200 V, covering the apparatus with foil and keeping the lights out. The
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">orange dye/free NFAT probe was close to the bottom of the gel at the
<br>end of the gel run. Images were obtained on an Odyssey scanner
<br>(LI-COR) using the 700 channel at the highest intensity and Image
<br>Studio 2.1 software (LI-COR) was used to quantify fluorescence of
<br>shifted bands. Protein concentrations used in these studies were op-
<br>timized from titration assays (data not shown) and fell within the
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">linear detection range of the Odyssey scanner. Control (contralateral
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">side of the hippocampus) and injured (ipsilateral side of the hip-
<br>pocampus) tissue samples were run on the same gel for direct statis-
<br>tical comparisons.
<br></span></div><span style="position:absolute; border: gray 1px solid; left:0px; top:1716px; width:585px; height:783px;"></span>
<div style="position:absolute; top:1716px;"><a name="3">Page 3</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:1753px; width:140px; height:8px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">1504 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:355px; top:1750px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:1778px; width:243px; height:400px;"><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">Immunofluorescent labeling of NFAT isoforms in brain sections</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">. On day
<br>7 of recovery after treatment with cortical contusion injury, rats were
<br>deeply anesthetized and perfused with 50 ml of saline followed by 100 ml
<br>of a solution of 4% paraformaldehyde, pH 7.4. After perfusion, the brains
<br>were removed from the skull, further fixed for an additional 4 h, and then
<br>put in a 30% sucrose solution. Coronal brain sections (40 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">m) were
<br>made and the sections stored in the sucrose solution in a </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫺</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">20 freezer. As
<br>needed, sections were removed and stained as free-floating sections in
<br>12-well tissue culture plates using a bent glass pipette to transfer brain
<br>section from well to well containing the appropriate solution. Brain sec-
<br>tions were rinsed 2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">with TBS buffer (100 m</span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">M </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">Tris, pH 7.5, 0.85%
<br>saline), treated with H</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">O</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">solution (3% H</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">O</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">, 10% methanol in TBS) for
<br>60 min, and then rinsed again with TBS buffer. Sections were pretreated
<br>with TBS-T (TBS with 0.1% Triton X-100) and blocked with TBS-BSA
<br>(2% BSA in TBS-T). First antibodies, the same ones used for the EMSAs
<br>(either NFAT1, Abcam, catalog #ab2722, 1:100 dilution, or NFAT4,
<br>Santa Cruz Biotechnology, catalog #sc-8405, 1:20 dilution) were diluted
<br>in TBS-BSA and brain sections were incubated overnight at 4 C with
<br>rotation on a shaker. The next morning, sections were washed 3</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">in
<br>TBS-T and then blocked in TBS-BSA. The secondary antibody (to the
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">mouse primaries) and an Alexa Fluor 488-tyramide from a tyramide
<br>signal amplification kit (Invitrogen, catalog #T20912) were used accord-
<br>ing to the manufacturer’s directions. After additional washes in TBS-T,
<br>the sections were blocked again in TBS-BSA and incubated with directly
<br>conjugated Alexa Fluor 594-monoclonal Ab to GFAP (Cell Signaling
<br>Technology, catalog #8152) at a 1:100 dilution overnight at 4°C. After
<br>washes in TBS-T, the sections were mounted on gelatin-coated micro-
<br>scope slides and coverslipped with DAPI-containing Prolong Gold Anti-
<br>fade Mounting Medium (Invitrogen, catalog #P36931). Fluorescent
<br>images were obtained on a confocal microscope (Nikon Eclipse Ti) and
<br>contralateral and ipsilateral sides were taken at the same settings so that
<br>quantitative comparisons could be made between the two sides. Images
<br>shown are single plane projections of focused stacks of images. NFAT4
<br>nuclear/cytosolic localization images (taken with a 100</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">objective) were
<br>obtained from enhanced green fluorescent protein (EGFP)-positive cells
<br>in the dendritic layers of CA1 and the dentate gyrus in a </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">Z</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">-series of 0.5
<br></span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">m steps. Images used for quantification were randomly acquired and
<br>measured by personnel blind to the experimental condition. Cytosolic
<br>and nuclear NFAT4 fluorescence intensities were quantified by Imaris
<br>8.1.3 software.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:2180px; width:243px; height:199px;"><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">AAV delivery</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">. AAV2/5 vectors constructed using </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">rep </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">and </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">cap </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">genes
<br>from AAV2 and AAV5 serotypes, respectively (Hildinger et al., 2001),
<br>were obtained from the UPENN virus core. Vectors expressed EGFP
<br>alone or EGFP fused to the NFAT inhibitory peptide VIVIT. Transgene
<br>expression was under the control of the human GFAP promoter (Gfa2)
<br>isolated and characterized by Dr. Michael Brenner’s laboratory at the
<br>University of Alabama–Birmingham (de Leeuw et al., 2006; Lee et al.,
<br>2008). Methods for the bilateral delivery of AAV vectors to rat hippocam-
<br>pus were adapted, with slight modifications, from our previous work on
<br>mice (Furman et al., 2012). Briefly, rats were placed in a stereotaxic frame
<br>under isoflurane anesthesia as described above. After a midline incision,
<br>holes were drilled bilaterally and needles attached to separate Hamilton
<br>syringes containing AAV vectors (10 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">12 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">ifu/ml) were lowered into the
<br>hippocampus and injected at a rate of 0.2 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l/min (8 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l total) using a
<br>stereotaxic microinjector (Stoelting). Syringe needles were left in place
<br>for 2 min after completion to limit reflux. Coordinates for injection
<br>relative to bregma were </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫹</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">3.8 mm anteroposterior, </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫹</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">1.8 mm mediolat-
<br>eral, and </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫺</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">2.8 mm dorsoventral. Wounds were closed and rats were
<br>returned to their home cages for </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">8 weeks before receiving a unilateral
<br>CCI injury, as described above.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:2380px; width:243px; height:89px;"><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">Astrocyte immunodepletion and AAV specificity</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">. At 4 weeks after AAV-
<br>Gfa2-EGFP injection, some rats were anesthetized under CO</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">and decap-
<br>itated, with hippocampi dissected away and stored in ice-cold Ca </span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:5px">⫹</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">/
<br>Mg </span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:5px">⫹</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">-free PBS solution. Hippocampal tissue then was minced finely in
<br>a Petri dish, treated with 0.125% trypsin-EDTA, and transferred to a
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">conical tube (in a total volume of 2 ml) using a 1000 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l pipet tip. After 15
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">min, samples were triturated first with a 1000 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l pipet tip, then with a 200
<br></span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l tip (placed over the end of a 1000 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l pipet tip). The sample was then
<br>diluted with 2 ml of PBS with 0.5% BSA (buffer) and incubated for an
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:1778px; width:243px; height:79px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">additional 15 min to allow larger fragments of undigested tissue to settle
<br>out. The supernatant was passed through a 70 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">m filter and the cells
<br>centrifuged 2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">at 300 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">g </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">for 10 min (to remove all trypsin) and resus-
<br>pended in buffer. After the final spin, cells were resuspended in </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">4 ml of
<br>buffer. A small sample was diluted 1:10, treated with trypan blue, and
<br>examined on a hemocytometer to determine both cell number and the
<br>quality of the single-cell suspension. Typical yields using this method
<br>were </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">1–5 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">10 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">8 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">cells.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:1856px; width:243px; height:261px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">For cell separation, </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">5 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">10 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">7 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">cells from each sample were pelleted at
<br>300 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">g </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">for 10 min and taken up in 100 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l buffer with 150 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l of mouse
<br>GLAST antibody (Miltenyi Biotec pure GLAST Ab). “Mock” separations
<br>(i.e., in which no GLAST antibody was added) were performed in paral-
<br>lel. Cells were then resuspended by pipetting up and down (never vor-
<br>texed) and incubated for 13 min at 4°C. Cells were pelleted (300 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">g for
<br>10 min), washed 3</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">(to remove excess antibody), resuspended in 200 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l
<br>of buffer containing 40 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l of preequilibrated Dynabeads (Invitrogen),
<br>and incubated at 4°C for another 15 min. The astrocyte-enriched (AE)
<br>fraction bound to the beads was captured to the side of the tube using a
<br>chilled Mag-Rack (GE Healthcare) and the astrocyte-depleted (AD) frac-
<br>tion removed. To ensure removal of all Dynabeads, the AD fraction
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">underwent a second round in the Mag-Rack and the suspension was
<br>extracted. This fraction was then pelleted to concentrate the cells. The AE
<br>fraction was washed 3</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">in buffer, capturing it in the Mag-Rack each time
<br>to maximize astrocyte enrichment. After each wash, the fraction was
<br>resuspended and placed in the Mag-Rack to maximize astrocyte enrich-
<br>ment. At the end of the separation procedure, the AD and AE fractions,
<br>along with mock-enriched (ME) and mock-depleted (MD) fractions
<br>(i.e., fractions not exposed to GLAST antibody) were dissolved in 60 – 80
<br></span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">l of 2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">sample buffer, heated at 65°C for 20 min, and then transferred
<br>to separate lanes of a 4 –20% Criterion gradient gel (Bio-Rad) for SDS-
<br>PAGE. The gel was then transferred to Immobilon-FL PVDF membranes
<br>(Millipore, catalog #IPFL 00010). Western blots were performed using
<br>primary antibodies to GFAP (rabbit; Cell Signaling Technology), EGFP
<br>(rabbit; Abcam), and </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␤</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">-actin (mouse; Sigma-Aldrich).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:2119px; width:243px; height:119px;"><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">Preparation of hippocampal slices</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">. Methods for preparing hippocampal
<br>slices from brain-injured rats are nearly identical to our previous work
<br>(Norris and Scheff, 2009). Briefly, at 7 d after CCI, rats were killed under
<br>CO</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">anesthesia and decapitated. Brains were rapidly removed and placed
<br>in ice-cold, oxygenated (95% O</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">, 5% CO</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">) artificial CSF (ACSF) con-
<br>taining the following (in m</span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">M</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">): 124 NaCl, 2 KCl, 1.25 KH2PO</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">4</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">, 2 MgSO</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">4</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">,
<br>0.5 CaCl2, 26 NaHCO</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">3</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">, and 10 dextrose, pH 7.4. Hippocampi were
<br>bilaterally dissected and sectioned coronally into </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">400 – 450 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">m slices
<br>using a McIlwain Tissue Chopper (Stoelting). Slices were then trans-
<br>ferred to a custom interface holding chamber (Mathis et al., 2011) and
<br>incubated with warmed (32°C) oxygenated ACSF containing 2 m</span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">M </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">CaCl
<br>until electrophysiological recordings (usually 1.5–5 h).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:2240px; width:243px; height:119px;"><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">Electrophysiological analysis of CA1 synaptic function</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">. Slices were sub-
<br>merged in oxygenated ACSF (32°C) and perfused at a rate of 1–2 ml/min
<br>in an RC22 chamber (Warner Instrument). Schaffer collaterals were ac-
<br>tivated with a bipolar platinum/iridium electrode located in stratum
<br>radiatum near the CA3–CA1 border. Stimulus intensity was controlled
<br>by a constant current stimulus isolation unit (World Precision Instru-
<br>ments) and stimulus timing was controlled by Clampex 9.2 software
<br>(Molecular Devices). Field potentials were recorded in CA1 stratum ra-
<br>diatum using a glass micropipette (1– 6 M</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⍀</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">) and filled with ACSF con-
<br>taining an Ag/AgCl wire. Physiologic activity was amplified 100</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫻</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">,
<br>Bessel-filtered at 1 kHz, and digitized at 10 kHz using a Multiclamp 700B
<br>amplifier and a Digidata 1320 digitizer (Molecular Devices).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:2359px; width:243px; height:110px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">To assess basal synaptic strength, 100 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">s stimulus pulses were given at
<br>nine intensity levels (range 30 –500 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">A) at a rate of 0.1 Hz. Five field
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">potentials at each level were averaged, and measurements of fiber volley
<br>(FV) amplitude (in millivolts) and EPSP slope (in millivolts/millisecond)
<br>were performed offline using Clampfit software (Molecular Devices). FV
<br>amplitudes were plotted against stimulation intensity to estimate the
<br>relative level of presynaptic excitability and EPSP slope measures were
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">plotted against their corresponding FV amplitudes to estimate the rela-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">tive strength of CA3–CA1 synapses. Synaptic strength curves for each
<br>hemisphere were fit (SigmaPlot 12; Systat Software) with a sigmoidal
<br>equation of the form:
<br></span></div><span style="position:absolute; border: gray 1px solid; left:0px; top:2549px; width:585px; height:783px;"></span>
<div style="position:absolute; top:2549px;"><a name="4">Page 4</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:2583px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:403px; top:2586px; width:140px; height:8px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">• 1505
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:161px; top:2612px; width:4px; height:9px;"><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">a
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:122px; top:2609px; width:49px; height:32px;"><span style="font-family: ALPLDF+MathematicalPi-Three; font-size:31px">冉 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">1 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">⫹ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">exp</span><span style="font-family: ALPLDF+MathematicalPi-Three; font-size:31px">冉 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">⫺
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:195px; top:2609px; width:9px; height:31px;"><span style="font-family: ALPLDF+MathematicalPi-Three; font-size:31px">冊冊
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:172px; top:2623px; width:23px; height:10px;"><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">x </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">⫺ </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">x</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">0
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:181px; top:2637px; width:4px; height:9px;"><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">b
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:2654px; width:243px; height:49px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">Where </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">a </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">equals the maximal amplitude of the curve, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">b </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">equals the curve
<br>slope, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">x </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">equals the FV amplitude, and </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">x</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">0 equals the FV amplitude re-
<br>quired for half-maximal EPSP amplitude. Synaptic strength was also
<br>estimated by averaging the EPSP/FV ratio across the top three stimulus
<br>levels of the input output curve.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:2704px; width:243px; height:229px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">Methods for inducing and measuring LTD are similar to those used
<br>in our previous work (Norris et al., 1996; Sama et al., 2012; Norris et
<br>al., 2016). After input/output curves, single-stimulus pulses were de-
<br>livered at a rate of 0.033 Hz to establish a baseline. Although the </span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">1</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">⁄</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">maximal stimulus intensity from the input/output curve is often used
<br>for setting the baseline and LTD stimulation levels, we instead used
<br>the stimulus intensity necessary to elicit an </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">1 mV EPSP. This pro-
<br>cedure was implemented to minimize possible hemispheric differ-
<br>ences in the level of postsynaptic depolarization achieved during LTD
<br>induction (see discussion in Norris and Scheff, 2009; Mathis et al.,
<br>2011). It is well established that the induction of both LTD and long-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">term potentiation (LTP) are strongly dependent on postsynaptic de-
<br>polarization levels (Malinow and Miller, 1986; Wigstrom and
<br>Gustafsson, 1986; Mulkey and Malenka, 1992). We have found that,
<br>relative to the contralateral hemisphere, slices from the ipsilateral
<br>hippocampus typically show reduced EPSP amplitudes (less depolar-
<br>ization) in response to the same level of presynaptic stimulation at 7 d
<br>aftr CCI (Norris and Scheff, 2009). Using the </span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">1</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">⁄</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">maximal stimulus
<br>intensity in the CCI model would therefore necessarily lead to the
<br>elicitation of smaller EPSP amplitudes during LTD stimulation for
<br>ipsilateral relative to contralateral slices, which may in turn negatively
<br>affect the extent to which postsynaptic plasticity mechanisms are
<br>engaged.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:2934px; width:243px; height:79px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">After a stable baseline period of no less than 20 min, slices received a 15
<br>min train of 1 Hz stimulation at baseline stimulation intensity, followed
<br>by another 60 min baseline period (stimulation rate </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫽ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">0.033 Hz). Within
<br>each hemisphere, EPSP measures from the last 10 min of the post-1 Hz
<br>stimulation baseline were averaged across slices and expressed as a per-
<br>centage of the pre-1 Hz stimulation baseline level. Therefore, for all
<br>electrophysiologic biomarkers, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">n </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">is equal to the number of rats used
<br>rather than the number of slices.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:3014px; width:243px; height:289px;"><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">Western blot</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">. On day 7 of recovery from CCI injury, hippocampi
<br>(contralateral control and ipsilateral injured) were harvested, put into
<br>Microfuge tubes, and snap frozen in liquid N</span><span style="font-family: ALPGDF+Minion-Regular; font-size:5px">2</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">. Samples were stored at
<br></span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫺</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">80°C until needed. Samples were homogenized in PBS with a panel of
<br>protease and phosphatase inhibitors as described previously (Ansari et
<br>al., 2013). Lowry protein assays were performed to normalize protein
<br>levels and 25–75 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">g of protein was used per gel well (depending on the
<br>antibody used for Western analysis). Proteins were resolved on 4 –20%
<br>Criterion gradient gels (Bio-Rad) and transferred to Immobilon-FL
<br>PVDF membranes (Millipore, catalog #IPFL 00010). After transfer,
<br>membranes were blocked in 50% Odyssey protein blocking reagent in
<br>PBS and then incubated in primary antibodies in 50% Odyssey protein
<br>blocking reagent (LI-COR) in PBS with 0.2% Tween overnight at 4°C on
<br>a shaking platform. Westerns were performed with the following primary
<br>antibodies: GFAP (Cell Signaling Technology, catalog #3670S), Iba1
<br>(Wako, catalog #019-19741), PSD-95 (Cell Signaling Technology, cata-
<br>log #3450S), synapsin-1 (Cell Signaling Technology, catalog #6710S),
<br>GluR1 (Millipore, catalog #AB1504), NR2A (Millipore 07-632), NR2B
<br>(Millipore, catalog #05-920), CNA</span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␣ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">(Millipore, catalog #07-1492),
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">GAPDH (Abcam, catalog #ab9484), hevin (R&amp;D Systems, catalog
<br>#MAB2836), and SPARC (R&amp;D Systems, catalog #MAB942). Mem-
<br>branes were then washed in PBS/0.1% Tween, incubated in LI-COR
<br>800-conjugated anti-mouse and 680-conjugated anti-rabbit secondary
<br>antibodies, washed, and imaged on an Odyssey Sa Imager System
<br>(LI-COR) on both the green (800) and red (680) channels. Quantifica-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">tion of bands was performed using Image Studio 2.1 software (LI-COR).
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">Expression was normalized to loading control GAPDH for each sample.
<br></span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">Statistical analyses</span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">. Unless otherwise noted, outcome measures were
<br>assessed in both the contralateral (uninjured) and ipsilateral (injured)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:2611px; width:243px; height:39px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">hemispheres and compared across treatment groups using repeated-
<br>measures ANOVA. When appropriate, Fisher’s protected least signifi-
<br>cant difference test was used for </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">post hoc </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">analyses. Significance for all
<br>statistical comparisons was set at </span><span style="font-family: ALPIDL+Minion-Italic; font-size:9px">p </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">ⱕ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:9px">0.05.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:2662px; width:243px; height:200px;"><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:13px">Results
<br></span><span style="font-family: ALPLNI+Minion-Bold; font-size:10px">Upregulation of NFAT expression is isoform and
<br>cell-type specific
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">The role of CN/NFAT signaling in TBI was assessed using a uni-
<br>lateral CCI model, which results in a substantial loss of CA3
<br>neurons (Baldwin et al., 1997) and CA3–CA1 synaptic contacts in
<br>stratum radiatum of the ipsilateral hemisphere, followed by the
<br>partial reinnervation of CA1 during the first few weeks after in-
<br>jury (Scheff et al., 2005). Significant changes in CN expression
<br>and/or activity have also been reported in this and other models
<br>of acute injury (Huang et al., 2005; Liu et al., 2005; Shioda et al.,
<br>2006; Bales et al., 2010; Rosenkranz et al., 2012), although the
<br>nature of the change shows considerable variability from study to
<br>study. All end point measures were taken at 7 d after CCI, at
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">which time CA3 presynaptic input into CA1 of the ipsilateral
<br>hemisphere has plateaued (and is functionally comparable to the
<br>contralateral hemisphere), but CA1 postsynaptic strength is still
<br>impaired (Norris and Scheff, 2009; Norris et al., 2016).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:2864px; width:243px; height:153px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Figure 1, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">A </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">and </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">B</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, shows the appearance of a 45– 48 kDa CN
<br>fragment in the hippocampus, ipsilateral to CCI, at 7 d after
<br>injury (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫽ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">5). This fragment is similar in size to the
<br>constitutively active CN (aCN) proteolytic fragment expressed in
<br>rat primary hippocampal cultures exposed to excitotoxic insults
<br>(Liu et al., 2005) or oligomeric A</span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:9px">␤</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">peptides (Mohmmad Abdul et
<br>al., 2011) (also see Fig. 1</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">A</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, 45 kDa aCN lane). Previous work has
<br>shown that aCN can appear at high levels in nervous tissue of
<br>intact rodents as a result of acute injury (Huang et al., 2005; Liu et
<br>al., 2005; Shioda et al., 2006), elevated amyloid levels (Abdul et
<br>al., 2009), or progressive neurodegeneration (Wu et al., 2010;
<br>Mohmmad Abdul et al., 2011), where it may contribute to syn-
<br>aptic deficits, cell death, and neuroinflammation, among other
<br>pathologic processes (Norris, 2014).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:3018px; width:243px; height:285px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">To investigate possible changes in the CN-dependent tran-
<br>scription factor NFAT, we used an electrophoretic mobility shift
<br>assay (EMSA) based on a well characterized NFAT-binding oli-
<br>gonucleotide probe derived from the IL4 enhancer region (Neal
<br>and Clipstone, 2001). Using IRDye-labeled probe, we observed a
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">prominent protein-DNA complex (blue arrowheads, Fig. 1</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">C</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">)
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">and a more variable and faint complex (black arrowheads, Fig.
<br>1</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">C</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">) in hippocampal tissue fractions from both hemispheres of
<br>injured (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫽ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">8) and sham (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫽ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">5) rats at 7 d after injury. Both of
<br>these bands were displaced when EMSAs were performed in the
<br>presence of unlabeled wild-type probe, but not with a mutant
<br>probe, confirming that observed bands reflect NFAT-specific
<br>binding. The intensity of the higher-molecular-weight complex
<br>(blue arrowheads) was increased in the ipsilateral relative to the
<br>contralateral hemisphere of injured, but not sham-operated, rats
<br>at 7 d after CCI (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05). Supershift/blockshift experiments
<br>were then performed to identify which CN-dependent NFAT
<br>isoform(s) (NFATs 1– 4) gave rise to the DNA-protein com-
<br>plexes. The NFAT1 antibody caused a clear supershift, indicated
<br>by the red asterisk in Figure 1</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">C</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">. The NFAT2 and 3 antibodies did
<br>not perceptibly alter the basic EMSA, indicating that they were
<br>not part of the complex. Finally, the NFAT4 antibody completely
<br>blocked the formation of the DNA–protein complex (see blue
<br>asterisk in Fig. 1</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">C </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">for where the complex normally migrates). For
<br>purposes of quantification, each “pair” of contralateral control
<br>and ipsilateral hippocampal homogenates was assayed on one gel.
<br></span></div><span style="position:absolute; border: black 1px solid; left:122px; top:2623px; width:82px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:172px; top:2636px; width:23px; height:0px;"></span>
<span style="position:absolute; border: gray 1px solid; left:0px; top:3382px; width:585px; height:783px;"></span>
<div style="position:absolute; top:3382px;"><a name="5">Page 5</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:3419px; width:140px; height:8px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">1506 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:355px; top:3416px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:3444px; width:157px; height:153px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Because the NFAT4 antibody entirely
<br>blocked the formation of
<br>the DNA-
<br>protein complex (indicated by the blue ar-
<br>row), this band was quantified and used to
<br>estimate
<br>total NFAT4 binding. For
<br>NFAT1, the supershifted band, indicated
<br>by the red asterisks, was quantified for
<br>each sample set. The quantitative data are
<br>shown in Figure 1</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">D</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">. There was a clear and
<br>significant increase in the DNA-binding
<br>activities of NFATs 1 and 4 in the ipsilat-
<br>eral hippocampi of the CCI animals, with
<br>little change observed across hemispheres
<br>in the shams.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:3598px; width:157px; height:461px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Previous work has shown that NFATs
<br>1 and 4 can appear in astrocytes as the
<br>result of injury or disease (Abdul et al.,
<br>2009; Serrano-Pe´rez et al., 2011; Caraveo
<br>et al., 2014). To determine whether the
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">expression differences for NFATs 1 and 4
<br>revealed by EMSA analyses (Fig. 1</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">C</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">D</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">) are
<br>associated with activated astrocytes after
<br>CCI, we colabeled coronal sections from
<br>injured rats (7 d after CCI) with NFAT
<br>and GFAP antibodies and imaged sections
<br>using confocal microscopy. As shown in
<br>Figure 2, we observed a striking increase
<br>in GFAP labeling (shown in red) in the
<br>hippocampus of
<br>the ipsilateral hemi-
<br>sphere, consistent with robust injury-
<br>dependent astrocyte activation. Although
<br>both NFAT isoforms exhibited diffuse
<br>labeling in the hippocampus of the con-
<br>tralateral hemisphere, there were clear dif-
<br>ferences in the distribution of the two
<br>isoforms in regard to cell type expression
<br>and injury. NFAT1 showed very little
<br>colocalization with GFAP-positive astro-
<br>cytes in any region of the hippocampus
<br>examined regardless of hemisphere (Fig.
<br>2</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">A</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">).
<br>in
<br>NFAT1 labeling were characterized pri-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">marily by a shift to a punctate labeling pat-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">tern in the ipsilateral hippocampus and
<br>may be associated with proliferating mi-
<br>croglia or infiltrating peripheral cells. In
<br>contrast, NFAT4 showed extensive colo-
<br>calization with GFAP-positive astrocytes,
<br>especially in CA1 (Fig. 2</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">B</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). In the ipsilat-
<br>eral hippocampus, the labeling intensity
<br>for NFAT4 was generally increased in pro-
<br>portion to the increase in GFAP labeling
<br>intensity. There was little evidence for the
<br>expression of either NFAT isoform in
<br>neuronal cell bodies, particularly in pyra-
<br>midal neurons.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:3884px; width:115px; height:10px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Interhemispheric differences
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:4060px; width:243px; height:76px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Interestingly, NFAT4/GFAP coloca-
<br>lization showed marked heterogeneity
<br>across different regions of the hippocam-
<br>pus (Fig. 3). NFAT4 colocalization with GFAP was extensive in
<br>the stratum lacunosum/moleculare, stratum radiatum, and stra-
<br>tum oriens of CA1 (Fig. 3</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">A</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">–</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">C</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">), as well as the molecular layers and
<br>hilar regions of the dentate gyrus (Fig. 3</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">M</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">N</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">), but was much less
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:211px; top:3902px; width:332px; height:175px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:9px">Figure 1.
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">Changes in CN and NFAT signaling properties at 7 d after CCI. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Representative Western blot for the CN A subunit in rat
<br>hippocampalwhole-celllysatesfromratcontralateralandipsilateralhemispheresat7dafterCCI.Whole-celllysatesfromprimaryastrocyte
<br>cultures infected with adenovirus (Ad) expressing a constitutively active 45 kDa CN fragment (aCN) were run in parallel. Injury was associ-
<br>atedwithanincreaseintheproteolysisofCNtoa45–48kDafragment,similarinsizetothefragmentfoundinAd-aCN-infectedastrocyte
<br>cultures.</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">B</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">,Mean</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SDlevel(percentagecontralateralhemipherelevels)ofproteolysisinhippocampalhomogenatesincontralateraland
<br>ipsilateralhemispheres.</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.05,paired</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">t</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">test.</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">,RepresentativeEMSAforhippocampalhomogenatesfromtheipsilateralandcontralat-
<br>eral hemispheres of rats exposed to CCI or to sham surgery. NFAT-binding probe was added to homogenates with and without antibodies
<br>(Ab)toeachofthe4CN-dependentNFATisoformstoshowsupershiftsand/orblockshifts.UnlabeledWT(wt)andmutant(mt)DNAprobe
<br>was included in some conditions to demonstrate DNA-binding specificity of the labeled probe. Bands denoted by the blue arrowheads
<br>reflecttotalNFATbinding.RedasteriskspointtobandsthatweresupershiftedinresponsetoinclusionoftheNFAT1antibody.Blueasterisks
<br>appear next to lanes where the NFAT4 antibody was included with the DNA-binding probe and illustrate a clear block shift. The black
<br>arrowheads point to bands that were relatively insensitive to antibody treatment conditions and likely reflect nonspecific binding. No gel
<br>shiftsorblockshiftswereseenafterinclusionoftheNFAT2and3antibodies,suggestingthattheseisoformsdidnotsignificantlycontribute
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">tototalNFATbindingundertheseconditions.</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">D</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">,Mean</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SDDNA-bindingactivityexpressedaspercentageofshamcontralateralcondition
<br>levels. NFAT1 was assessed from the supershifted bands obtained with the NFAT1 antibody (see red asterisks in </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">). NFAT 4 was assessed
<br>fromthebandsassociatedwithbluearrowheadsin</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">.n.s.,Nonsignificantipsilateralversuscontralateral;*</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.05;</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫹</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.01ipsilateral
<br>versus contralateral, Fisher’s PLSD test.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:4091px; width:243px; height:44px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">apparent in the neuronal cell body layers (Fig. 3, cf. </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">H </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">vs </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">I</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">N </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">vs
<br></span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">O</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). Moreover, in contrast to an earlier study that used a kainic
<br>acid insult (Serrano-Pe´rez et al., 2011), we did not observe exten-
<br>sive colocalization of NFAT4 in astrocytes of CA3 even though
<br></span></div><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:239px; top:3445px; width:276px; height:447px;"></div><span style="position:absolute; border: gray 1px solid; left:0px; top:4215px; width:585px; height:783px;"></span>
<div style="position:absolute; top:4215px;"><a name="6">Page 6</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:4249px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:403px; top:4252px; width:140px; height:8px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">• 1507
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:432px; top:4277px; width:36px; height:10px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">to verify
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:386px; top:4277px; width:157px; height:142px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">that AAV-Gfa2-
<br>important
<br>mediated transgene expression occurred ex-
<br>clusively in astrocytes. Confocal microscopy
<br>was used to inspect the possible colocaliza-
<br>tion of AAV-dependent EGFP expression
<br>with neurons (MAP2b; Fig. 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">E</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">F</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">) and as-
<br>trocytes (GFAP; Fig. 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">D</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">G</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). As shown in
<br>Figure 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">G</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, EGFP expression in CA1 strongly
<br>colocalized with GFAP (Fig. 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">G</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">H</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">), but
<br>there was no overlap between EGFP and
<br>MAP2b (Fig. 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">F</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">H</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). Nearly identical obser-
<br>vations were made in other hippocampal
<br>subregions as well (data not shown).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:386px; top:4420px; width:157px; height:230px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">To further confirm that AAV-Gfa2
<br>vectors selectively targeted astrocytes,
<br>we performed immunodepletion exper-
<br>iments (Fig. 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">I </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). Hippocampi
<br>from
<br>AAV-Gfa2-EGFP-infected rats were ex-
<br>tracted and triturated into single-cell
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">suspensions, which were then placed in
<br>a Microfuge tube and treated with
<br>GLAST antibodies (to tag astrocytes)
<br>coupled to metal Dynabeads. Tubes
<br>were then placed in a magnetic rack to
<br>pull out bead-coupled cells from the
<br>suspension. The fraction bound to the
<br>beads is referred to as AE, whereas the
<br>unbound fraction is referred to as AD.
<br>Some suspensions were passed through
<br>the same protocol, but were not treated
<br>with GLAST antibodies and served as
<br>MD and ME control fractions. Western
<br>blots were then performed to determine
<br>which fraction contained EGFP.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:4651px; width:243px; height:186px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">As shown in Figure 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">J</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, the astrocyte-
<br>specific marker GFAP was found in the
<br>MD fraction (as expected) and also in the
<br>AE fraction, but not in the AD fraction.
<br>The prominent appearance of </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:9px">␤</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">-actin
<br>(which is expressed across all cell types) in
<br>the AD fraction demonstrates that the lack of GFAP expression
<br>was not attributable to a simple loss of total protein. These obser-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">vations validate the successful immunodepletion of astrocytes in
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">this protocol. If transgene expression after AAV-Gfa2 treatment
<br>is selective to astrocytes, then EGFP should show a similar expres-
<br>sion pattern to GFAP, which is exactly what was observed: EGFP
<br>appeared in MD and AE fractions, but not in AD fractions. Es-
<br>sentially the same results were observed in four separate animals.
<br>Combined with the confocal images shown in Figure 4, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">C</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">–</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">H</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,
<br>these data demonstrate that AAV-Gfa2 vectors selectively target
<br>astrocytes.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:4838px; width:243px; height:131px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">The VIVIT peptide, expressed by AAV-Gfa2 vectors, is de-
<br>rived from a critical endogenous CN-docking site (PxIxIT)
<br>found in the regulatory subregion of NFATs 1– 4 (Aramburu
<br>et al., 1999). Numerous studies have shown that VIVIT inhib-
<br>its the nuclear localization or the transcriptional activity of
<br>NFATs in diverse tissues and cell types (Yu et al., 2007). Pre-
<br>viously, we showed that VIVIT inhibited NFAT activity in
<br>primary astrocytes treated with proinflammatory or cytotoxic
<br>factors (Sama et al., 2008; Abdul et al., 2009). Confocal micro-
<br>graphs in Figure 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">K </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">show the cellular localization of NFAT4
<br>(red) in EGFP- or VIVIT-expressing astrocytes of AAV-
<br>infected rats. Note that nuclei are labeled blue (DAPI) and that
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:4616px; width:332px; height:79px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:9px">Figure 2.
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">Confocal microscopic images showing the expression of NFATs 1 and 4 in the hippocampus at 7 d after CCI. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">,
<br></span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">B</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, NFAT and GFAP labeling shown separately and together (merged) in the CA1 region of the hippocampus in contralateral
<br>and ipsilateral hemispheres at 7 d after CCI. For each NFAT isoform, images were obtained from the same coronal plane of
<br>the same animal and are shown with identical brightness and contrast settings. Both NFATs are expressed throughout
<br>stratum radiatum and stratum oriens in the contralateral and ipsilateral hemispheres. NFAT1 (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) exhibited a more punctate
<br>labeling pattern in the ipsilateral hemisphere, but there was little to no colocalization with GFAP-positive astrocytes
<br>regardless of injury. In contrast, NFAT4 (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">B</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) was extensively colocalized to GFAP-positive astrocytes (see numerous yellow/
<br>orange cells in merged images) in both hemispheres and was upregulated as a result of injury.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:4717px; width:243px; height:65px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">numerous activated astrocytes were found in this region
<br>after injury (Fig. 3</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">B</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">J</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">–</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">L</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). This discrepancy may be attributable to
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">differences in the type of cellular degeneration occurring after
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">kainic acid treatment versus CCI. Regardless, these observations
<br>suggest possible phenotype differences between astrocytes in dif-
<br>ferent hippocampal subregions.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:4794px; width:243px; height:175px;"><span style="font-family: ALPLNI+Minion-Bold; font-size:10px">Use of AAV-Gfa2-VIVIT to inhibit astrocytic CN/NFAT
<br>signaling selectively in intact rats
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">To investigate the impact of astrocytic CN/NFAT signaling on func-
<br>tional outcome after TBI, we used an AAV-mediated gene delivery
<br>approach. Adult rats received bilateral hippocampal injections of
<br>AAV2/5 vectors expressing the NFAT inhibitor VIVIT (coupled to
<br>EGFP) or EGFP alone (control, CT). Some rats received identical
<br>injections of vehicle as an additional control. At approximately 8
<br>weeks after AAV treatment, rats were subjected to a moderate CCI
<br>injury (Fig. 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">A</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). To limit transgene expression to astrocytes, AAV
<br>vectors expressed the human GFAP promoter (Gfa2) (de Leeuw et
<br>al., 2006; Lee et al., 2008). As shown in our earlier work, a single
<br>injection (8 </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:9px">␮</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">l) of high titer (10 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">12 </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">ifu/ml) AAV-Gfa2 vectors into the
<br>hippocampus results in wide spread infection across all hippocam-
<br>pal subregions (Fig. 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">B</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). Because CN is ubiquitously expressed and
<br>found at particularly high levels in hippocampal neurons, it was
<br></span></div><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:70px; top:4278px; width:276px; height:327px;"></div><span style="position:absolute; border: gray 1px solid; left:0px; top:5048px; width:585px; height:783px;"></span>
<div style="position:absolute; top:5048px;"><a name="7">Page 7</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:5085px; width:140px; height:8px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">1508 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:355px; top:5082px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:5110px; width:157px; height:219px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">the EGFP signal (green) has been re-
<br>moved for clarity. In EGFP-expressing
<br>astrocytes, NFAT4 is mostly present in
<br>the cytosol, but also appears throughout
<br>the nucleus (blue) in many cells (Fig.
<br>4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">K</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, arrows). In contrast, NFAT4 expres-
<br>sion in VIVIT-expressing astrocytes is
<br>largely excluded from the nucleus (Fig.
<br>4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">K</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, arrowheads), consistent with NFAT
<br>inhibition. The average nuclear-to-
<br>cytosolic ratios for NFAT4 measured
<br>from 32– 42 cells per treatment condi-
<br>tion across three animals per group
<br>(10 –16 cells per rat) are shown in Figure
<br>4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">L</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">. Therefore, AAV-Gfa2
<br>vectors
<br>not only provide selective targeting
<br>of astrocytes (Fig. 4</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">C</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">–</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">J </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">), they provide
<br>an effective way to limit the nuclear lo-
<br>calization and activation of NFATs in
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">these cells.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:5341px; width:243px; height:373px;"><span style="font-family: ALPLNI+Minion-Bold; font-size:10px">AAV-Gfa2-VIVIT protects synaptic
<br>function in ipsilateral hippocampus
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">The rat unilateral CCI model is associated
<br>with extensive loss of synaptic contacts in
<br>the CA1 region of the ipsilateral hip-
<br>pocampus (Scheff et al., 2005). Although
<br>there is a remarkable degree of structural
<br>and functional recovery with time after
<br>injury, deficits in basal synaptic strength
<br>are still evident at 7 d after injury in this
<br>model (Norris and Scheff, 2009), provid-
<br>ing a reasonable time point to investigate
<br>the impact of astrocytic CN/NFAT signal-
<br>ing on synaptic function. One advantage
<br>of the rat CCI model, compared with
<br>mouse models or fluid-percussion injury
<br>models, is that moderate injuries to the
<br>ipsilateral hemisphere in adult rats (as investigated here) cause
<br>very few measurable changes in the contralateral hemisphere. For
<br>instance, previous work on oxidative stress markers after unilat-
<br>eral CCI in rats found no changes in the contralateral hemisphere
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">of injured rats compared with either hemisphere of sham-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">operated rats or even to naive rats (Gilmer et al., 2009). Multiple
<br>presynaptic and postsynaptic protein markers, found at reduced
<br>levels in the ipsilateral hippocampus of rats after CCI, are also
<br>unchanged in the contralateral hemisphere compared with
<br>sham-operated controls (Ansari et al., 2013; Scheff et al., 2013).
<br>Similarly, our previous work using electrophysological measures
<br>of synaptic function taken at 2, 7, and 14 d after CCI showed
<br>comparable levels of basal synaptic strength and plasticity in the
<br>contralateral hemisphere of injured and sham-operated rats
<br>(Norris and Scheff, 2009). These results support the validity of
<br>using the contralateral hemisphere as a within-animal control for
<br>synaptic measures after unilateral CCI in rats.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:5715px; width:243px; height:87px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">To determine the extent to which astrocytic CN/NFAT signal-
<br>ing influences synaptic function after CCI, we measured basal
<br>hippocampal synaptic strength in slices from ipsilateral and con-
<br>tralateral hippocampi of AAV-treated rats (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫽ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">6 – 8 rats/group)
<br>at 7 d after injury (Fig. 5</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">A</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">–</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">D</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). Field potentials were recorded in
<br>stratum radiatum of area CA1 in response to electrical stimula-
<br>tion of CA3 Schaffer collaterals. Synaptic strength curves were
<br>generated by plotting EPSP slope values against FV amplitudes
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:211px; top:5425px; width:332px; height:89px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:9px">Figure 3.
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">Heterogenous expression of NFAT4 in hippocampus. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">B</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Low-power confocal micrographs of the same
<br>coronal slice (ipsilateral hemisphere) showing GFAP (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) and NFAT4 (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">B</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) labeling at 7 d after CCI. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Low- (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) and
<br>high-powered (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">D</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) confocal images of NFAT4 and GFAP shown alone (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">E</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) or merged (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">D</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) in area CA1 of the hippocam-
<br>pus of the ipsilateral hemisphere. Micrographs illustrate extensive colocalization of NFAT4 throughout astrocyte somata,
<br>nuclei and major processes. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">G</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">O</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, NFAT4 and GFAP labeling in CA1 (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">G</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">I </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">), CA3 (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">J</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">L</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">), and the dentate gyrus (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">M</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">O</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) of the
<br>ipsilateral hemisphere. In CA1 and the DG, NFAT4 is found in most astrocytes. The exception is for those astrocytes found
<br>immediately adjacent to neuronal cell body layers, many of which are apparently devoid of NFAT4 (e.g., see arrowheads in
<br></span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">G</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">I </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">). Although numerous GFAP-positive astrocytes were found throughout the CA3 region, relatively few of these cells
<br>exhibited NFAT4 colabeling.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:5528px; width:243px; height:54px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">across increasing stimulus intensities. As shown in Table 1, all
<br>synaptic strength curve parameters investigated here were statis-
<br>tically comparable across the contralateral hemisphere of injured,
<br>sham-operated, and naive adult (</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">2-month-old) Sprague Daw-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">ley rats.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:5583px; width:243px; height:186px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Hippocampal slices from the ipsilateral hemisphere of
<br>AAV-Gfa2-EGFP control rats showed a downward shift in the
<br>synaptic strength curve relative to the contralateral hemi-
<br>sphere within the same animals (Fig. 5</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">A</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). Moreover, the
<br>EPSP-FV ratio for the ipsilateral hemisphere was reduced in
<br>AAV-Gfa2-EGFP control rats by </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">130% relative to the con-
<br>tralateral side ( </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.01),
<br>indicative of reduced synaptic
<br>strength (Fig. 5</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">D</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). In contrast, synaptic strength curves were
<br>qualitatively and quantitatively similar across hemispheres in
<br>rats pretreated with AAV-Gfa2-VIVIT-EGFP (Fig. 5</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">B</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">) and
<br>strongly resembled synaptic strength curves recorded in un-
<br>treated sham rats (Fig. 5</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">C</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">) and naive rats (Table 1). The
<br>EPSP-FV ratio in AAV-Gfa2-VIVIT-EGFP rats showed only a
<br>23% reduction in the ipsilateral hemisphere, which was simi-
<br>lar to the ipsilateral hemisphere of sham rats (</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">4% reduction)
<br>and significantly less ( </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05) than the reduction found in
<br>AAV-Gfa2-EGFP control rats (Fig. 5</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">D</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:5770px; width:243px; height:32px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">We next investigated the extent to which astrocytic CN/
<br>NFAT signaling influences synaptic plasticity after TBI. Al-
<br>though LTP is commonly measured in injury and disease
<br></span></div><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:213px; top:5111px; width:327px; height:303px;"></div><span style="position:absolute; border: gray 1px solid; left:0px; top:5881px; width:585px; height:783px;"></span>
<div style="position:absolute; top:5881px;"><a name="8">Page 8</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:5915px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:403px; top:5918px; width:140px; height:8px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">• 1509
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:386px; top:5943px; width:157px; height:406px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">model systems, our previous work with
<br>the rat CCI model did not reveal LTP
<br>deficits in the ipsilateral hemisphere at
<br>7 d after CCI (Norris and Scheff, 2009).
<br>In contrast, we recently found that the
<br>induction of LTD in CA1 using a 15
<br>min/1 Hz stimulus train is significantly
<br>enhanced in the ipsilateral hemisphere
<br>at both 7 and 14 d after injury (Norris et
<br>al., 2016). To confirm these observa-
<br>tions, we used a similar 1 Hz stimulus
<br>paradigm to induce LTD in the ipsilat-
<br>eral and contralateral hemispheres of
<br>injured rats (7 d after CCI) and sham-
<br>operated rats in the absence of AAV
<br>treatment. As shown in Figure 5</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">E</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, slices
<br>from sham rats and slices from the con-
<br>tralateral hemisphere of
<br>injured rats
<br>showed no significant depression (96%
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">and 101% of baseline, respectively) after
<br>1 Hz stimulation. In contrast, the same
<br>stimulus paradigm caused a modest
<br>(82% of baseline) but significant ( </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.01) depression in ipsilateral slices from
<br>injured rats, confirming that CCI increases
<br>the susceptibility to LTD in the ipsilateral
<br>hemisphere. Similar
<br>results,
<br>ipsilateral slices from AAV-Gfa2-EGFP-
<br>treated rats showed significant LTD (</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬃</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">83%
<br>of baseline, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05) after 1 Hz stimulation
<br>(Fig. 5</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">F</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). In contrast, LTD was completely
<br>prevented in ipsilateral slices from rats
<br>treated with AAV-Gfa2-VIVIT (103% of
<br>baseline). These results suggest that the as-
<br>trocytic CN/NFAT pathway helps to drive
<br>synapse dysfunction in the ipsilateral hip-
<br>pocampus after CCI injury.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:474px; top:6229px; width:34px; height:10px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">to these
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:386px; top:6361px; width:157px; height:142px;"><span style="font-family: ALPLNI+Minion-Bold; font-size:10px">AAV-Gfa2-VIVIT prevents the loss of
<br>synapse-related proteins in
<br>ipsilateral hippocampus
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">In addition to impaired synaptic function
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">and altered plasticity, CCI is also associ-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">ated with the loss of several key synaptic
<br>proteins in the ipsilateral hippocampus
<br>within the first week after injury, includ-
<br>ing the postsynaptic anchoring protein
<br>PSD-95, the presynaptic vesicle dock-
<br>ing protein synapsin 1, AMPA/kainate-
<br>type glutamate receptor isoforms (e.g.,
<br>GluR1), and NMDA-type glutamate re-
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:384px; top:6514px; width:8px; height:9px;"><span style="font-family: AMHMOP+Universal-ChemicalPi; font-size:9px">4
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:384px; top:6535px; width:159px; height:99px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">blue (DAPI). Top panels are 2D confocal images and the bot-
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">tom panels are 3D-rendered images generated from </span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">Z </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">stacks.
<br>Note that, for clarity, the EGFP signal is not shown. Arrows
<br>point to cells where NFAT4 is found distributed across both the
<br>cytosolic and nuclear compartments. Arrowheads point to
<br>cells where NFAT4 is largely excluded from the nucleus. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">L</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">,
<br>Mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SD for the nuclear-to-cytosolic ratio for NFAT4 in rats
<br>treated with AAV-Gfa2-EGFP or AAV-Gfa2-VIVIT (</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫽ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">3 rats
<br>per group). VIVIT-treated rats show a significant reduction in
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">the nuclear localization of NFATs. *</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.01, Student’s </span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">t </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">test.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:6485px; width:332px; height:149px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:9px">Figure 4.
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">AAV-Gfa2 vectors for targeting astrocytic CN/NFAT signaling. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, AAV-Gfa2 vectors expressing EGFP alone (CT) or EGFP
<br>fused with the NFAT-inhibitory peptide VIVIT were bilaterally injected into the hippocampus of adult rats. At 1–2 months after
<br>injection, rats received a unilateral CCI and biomeasures were taken at 7 d after injury. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">B</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Extensive EGFP expression throughout the
<br>molecular layers of the rat hippocampus at 5 weeks after injection. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">H</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Confocal micrographs showing labeling patterns for EGFP
<br>(</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">), GFAP (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">D</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">G</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">), and the neuronal marker MAP2B (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">E</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) from an AAV-Gfa2-EGFP-infected rat. Higher-magnification images of
<br>the regions shown in </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">and </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">G </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">are shown in </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">H</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">. There was extensive colocalization between EGFP and GFAP, but nearly no colocal-
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">ization between EGFP and MAP2b (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">H </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">). </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">I</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Diagram illustration of the protocol used to immunodeplete astrocytes from intact
<br>hippocampal tissue of AAV-Gfa2-EGFP infected rats. Single-cell suspensions were prepared from hippocampal tissue (Steps 1 and
<br>2) and then added to a Microfuge tube. GLAST antibody was added (Step 3) to tag astrocytes. Metal Dynabeads were then added
<br>(Step 4) and tubes were placed in a magnetic rack. The supernatant containing unbound cells was collected (Step 5) and are
<br>referred to as the AD fraction, whereas the antibody-bound fraction contained in the pellet (Step 6) is referred to as the AE fraction.
<br></span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">J</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Representative Western blot showing the expression of GFAP, EGFP, and </span><span style="font-family: ALPIOH+MathematicalPi-One; font-size:8px">␤</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">-actin loading control in AD and AE fractions. MD and
<br>ME fractions (no GLAST antibody added) were run in parallel as controls. EGFP appears in the AE fraction, but not in the AD fraction,
<br>confirming that AAV-Gfa2 targets astrocytes selectively. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">K</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Confocal micrographs showing the cellular localization of NFAT4 (red)
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">in EGFP-expressing cells in rats infected with AAV-Gfa2-EGFP (CT) or AAV-Gfa2-VIVIT-EGFP. Note that astrocyte nuclei are labeled
<br></span></div><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:44px; top:5950px; width:327px; height:524px;"></div><span style="position:absolute; border: black 1px solid; left:384px; top:6532px; width:159px; height:0px;"></span>
<span style="position:absolute; border: gray 1px solid; left:0px; top:6714px; width:585px; height:783px;"></span>
<div style="position:absolute; top:6714px;"><a name="9">Page 9</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:6751px; width:140px; height:8px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">1510 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:355px; top:6748px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:386px; top:6776px; width:157px; height:208px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">ceptor isoforms (e.g., NR2A and NR2B)
<br>(Ansari et al., 2013; Scheff et al., 2013). To
<br>determine whether these changes are sen-
<br>sitive to astrocytic CN/NFAT signaling,
<br>we harvested contralateral and ipsilateral
<br>hippocampus at 7 d after CCI from sham
<br>rats (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫽ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">4) and rats treated with AAV-
<br>Gfa2-VIVIT vectors (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫽ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">6) and used
<br>Western blot to quantify synaptic pro-
<br>tein levels. For controls, some rats (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫽
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">6) received bilateral injections of AAV-
<br>Gfa2 expressing EGFP alone, whereas
<br>other rats (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫽ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">6) received vehicle injec-
<br>tions. Because the two control groups
<br>showed no significant differences on
<br>any of the outcome measures, statistical
<br>comparisons were made only for the
<br>AAV-Gfa2-EGFP and AAV-Gfa2-VIVIT
<br>treatment groups.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:445px; top:7084px; width:11px; height:10px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">for
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:386px; top:6985px; width:157px; height:351px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">For AAV-Gfa2-EGFP-treated rats,
<br>the postsynaptic protein PSD-95 and
<br>the GluR1 AMPA receptor subunit were
<br>each significantly reduced, by 56% and
<br>82%, respectively,
<br>in the ipsilateral,
<br>relative to the contralateral, hippocam-
<br>pus (Fig. 6 </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">A</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">D </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">and </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">C</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">F </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). However, the
<br>loss of PSD-95 and GluR1 protein was
<br>(19% and 27%,
<br>comparably small
<br>respectively)
<br>rats
<br>treated with
<br>AAV-Gfa2-VIVIT. Although levels for
<br>synapsin 1 were not reduced in the
<br>ipsilateral hippocampus of AAV-Gfa2-
<br>EGFP at 7 d after CCI, the AAV-Gfa2-
<br>VIVIT group showed a significant 110%
<br>increase in the ipsilateral hemisphere
<br>( </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05) (Fig. 6 </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">B</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">E</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). Similar to
<br>PSD-95 and GluR1, we also observed a
<br>significant reduction in NR2A (</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫺</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">26 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫾
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">57% mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫾ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">SD, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05) and a small,
<br>nonsignificant reduction in NR2B levels
<br>(</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫺</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">20 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫹ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">35% mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫾ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">SD, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬎ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05) in
<br>AAV-Gfa2-EGFP rats (data not shown).
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">However, these changes were not signif-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">icantly altered by AAV-Gfa2-VIVIT
<br>(NR2A </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫺</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">26 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫾ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">27% mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫾ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">SD, </span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05; NR2B </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫺</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">23 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫾ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">24% mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⫾ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">SD,
<br></span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬎ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05). Therefore,
<br>together with
<br>measures of basal synaptic strength (Fig.
<br>5</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">A</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">–</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">D</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">), the results show that AAV-Gfa2-
<br>VIVIT protects against the loss of sev-
<br>eral key synaptic proteins after CCI.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:384px; top:7367px; width:8px; height:9px;"><span style="font-family: AMHMOP+Universal-ChemicalPi; font-size:9px">4
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:384px; top:7387px; width:159px; height:80px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">EPSP slopes) and bar graphs (right) showing mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SD EPSP
<br>values (% baseline) at 60 min after 1 Hz stimulation in slices
<br>collected from the ipsilateral (injured) hemispheres of AAV-
<br>treated rats. Insets show representative waveforms as de-
<br>scribed for </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">E</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">. Note that LTD is present in the ipsilateral
<br>hemisphere of rats pretreated with AAV-Gfa2-EGFP control
<br>vector (CT), but not in rats treated with AAV-Gfa2-VIVIT. *</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.05, Fisher’s PLSD test.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:7308px; width:332px; height:159px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:9px">Figure 5.
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">Effects of AAV-Gfa2-VIVIT on synaptic strength and plasticity. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">B</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, CA1 synaptic strength curves constructed from the
<br>mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SEM EPSP slope versus the mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SEM FV amplitude for hippocampal slices from the contralateral and ipsilateral
<br>hemispheres of rats treated with control (CT) AAV-Gfa2-EGFP (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) or with AAV-Gfa2-VIVIT (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">B</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">). Slices from contralateral and
<br>ipsilateral hemispheres of sham-operated rats (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) are also shown for comparison. Insets in </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">show representative EPSP wave-
<br>forms in each hemisphere matched on the basis of FV amplitude. Note, that for AAV-Gfa2-EGFP CT rats (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">), the synaptic strength
<br>curve exhibited a marked downward shift in the ipsilateral relative to the contralateral hemisphere. In contrast, synaptic strength
<br>curves across hemispheres are qualitatively and quantitatively similar in sham rats (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) and rats treated with AAV-Gfa2-VIVIT (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">B</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">). </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">D</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">,
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">Mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SD of the EPSP-to-FV ratio in the ipsilateral hemisphere of AAV-treated and sham rats expressed as percentage change
<br>from the contralateral hemisphere. A reduction in the EPSP-to-FV ratio is only observed for AAV-Gfa2-EGFP CT rats.*</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.01
<br>ipsilateral versus contralateral, Fisher’s PLSD test. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">E</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Left, Time plots showing mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SEM EPSP slope values (% baseline) from
<br>slices collected from the contralateral and ipsilateral hemispheres of untreated rats (i.e., no AAV) and the ipsilateral hemisphere of
<br>sham-operated rats. EPSPs were recorded before and for 60 min after delivery of a 15 min train of 1 Hz stimulation (bar).
<br>Representative waveforms in slices from each hemisphere of CCI rats measured before (1) and 60 min after (2) 1 Hz stimulation are
<br>shown in the inset. Calibration bars are 0.5 mV/5 ms. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">E</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Right, Mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SD EPSP slope at 60 min after 1 Hz stimulation in
<br>contralateral and ipsilateral hemispheres and also in the ipsilateral hemisphere of sham-operated rats. Significant LTD was only
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">observed in slices from the ipsilateral hemisphere of injured rats, *</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.05 Fisher’s PLSD test. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Left, LTD time plots (mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SEM
<br></span></div><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:-9px; top:6913px; width:549px; height:592px;"><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:44px; top:6782px; width:328px; height:515px;"></div></div><span style="position:absolute; border: black 1px solid; left:384px; top:7385px; width:159px; height:0px;"></span>
<span style="position:absolute; border: gray 1px solid; left:0px; top:7547px; width:585px; height:783px;"></span>
<div style="position:absolute; top:7547px;"><a name="10">Page 10</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:7581px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:403px; top:7584px; width:140px; height:8px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">• 1511
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:7607px; width:238px; height:33px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:9px">Table 1. CA3–CA1 synaptic strength curve parameters (mean </span><span style="font-family: AMJEMN+MathematicalPi-Four; font-size:8px">ⴞ </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:9px">SD) for naive rats,
<br>sham-operated rats, and AAV-treated rats 7 d after CCI
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">Condition
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:96px; top:7631px; width:36px; height:84px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">EPSP/FV ratio
<br>1.71 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.72
<br>1.49 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.27
<br>1.58 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.19
<br>1.87 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.30
<br>1.15 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.65*
<br>1.66 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.23
<br>1.81 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.43
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:7647px; width:102px; height:91px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">Naive
<br>Sham contra
<br>Sham ipsi
<br>EGFP/CT contra
<br>EGFP/CT ipsi
<br>VIVIT contra
<br>VIVIT ipsi
<br></span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:7px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:7px">⫽ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">6 –10 rats/group.
<br>*</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:7px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:7px">⬍ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">0.05 versus EGFP/CT contra, Fisher’s PLSD.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:147px; top:7631px; width:42px; height:84px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">Curve amplitude
<br>1.31 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.25
<br>1.20 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.26
<br>1.34 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.16
<br>1.40 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.12
<br>0.78 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.22*
<br>1.42 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.64
<br>1.41 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.70
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:204px; top:7631px; width:33px; height:84px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">Curve slope
<br>0.15 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.05
<br>0.11 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.03
<br>0.13 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.03
<br>0.11 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.03
<br>0.12 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.06
<br>0.12 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.05
<br>0.12 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.06
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:251px; top:7631px; width:33px; height:84px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">Curve ½ max
<br>0.35 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.11
<br>0.28 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.07
<br>0.33 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.11
<br>0.29 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.07
<br>0.30 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.12
<br>0.32 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.14
<br>0.37 </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.13
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:7609px; width:243px; height:175px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">We next tested whether AAV-Gfa2-VIVIT modulates other
<br>glial-based mechanisms directly involved in synaptic remod-
<br>eling. SPARC and SPARCL1 (hevin) are secreted matricellular
<br>factors that modulate synaptogenesis during development and
<br>possibly after neural injury (Jones et al., 2011; Kucukdereli et
<br>al., 2011; Albrecht et al., 2012; Blakely et al., 2015). Hevin has
<br>been shown to increase the number and size of synapses be-
<br>tween developing neurons in culture, and SPARC appears to
<br>counter these actions (Kucukdereli et al., 2011). Several stud-
<br>ies have reported an increase in SPARC and hevin levels in
<br>activated astrocytes after injury (Jones et al., 2014). Moreover,
<br>a microarray study from our group observed significant
<br>changes in hevin and SPARC gene tran-
<br>scripts in primary neuron/astrocyte cul-
<br>tures as a result of CN overexpression
<br>(Norris et al., 2005).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:7785px; width:243px; height:515px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Western blots of ipsilateral and con-
<br>tralateral hippocampus from rats at 7 d
<br>after CCI revealed differential sensitivities
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">of SPARC and hevin to injury and AAV
<br>treatment (Fig. 7</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">E</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">–</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">H</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). Although SPARC
<br>was readily detected in both hemispheres,
<br>it was relatively unaffected by either injury
<br>or AAV treatment (Fig. 7</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">E</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">F</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). In con-
<br>trast, hevin showed very low expression in
<br>the contralateral hemisphere, but exhib-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">ited increased levels in the ipsilateral hip-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">pocampus (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05) regardless of virus
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">treatment, indicative of a putative com-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">pensatory reaction to synapse loss with in-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">jury (</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Fig. 7</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">G</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">,</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">H</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">). Remarkably, hevin was
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">also significantly affected by AAV-Gfa2-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">VIVIT treatment. Among the proteins in-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">vestigated in this study, hevin was the only
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">one to show a change in expression in the
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">contralateral hemisphere across virus
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">treatment
<br>groups, with significantly
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">greater levels appearing in rats treated
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">with AAV-Gfa2-VIVIT (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.05). More-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">over, the effects of injury and AAV-Gfa2-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">VIVIT were synergistic, such that the
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">highest levels of hevin were found in the
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">ipsilateral hemisphere of AAV-Gfa2-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">VIVIT-treated rats (</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬍ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">0.001). These re-
<br>sults
<br>that AAV-Gfa2-VIVIT may increase and/or
<br>promote synaptic recovery after injury by driving the expression
<br>of the prosynaptogenesis factor hevin.
<br></span><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:13px">Discussion
<br></span><span style="font-family: ALPLNI+Minion-Bold; font-size:10px">Astrocyte activation and the CN/NFAT pathway after
<br>acute injury
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Recent advances in genetic approaches, including the use of cell-
<br>type-specific promoters to selectively target astrocyte signaling path-
<br>ways, have greatly increased our understanding of the functional
<br>impact of activated astrocytes. Several targeted approaches to limit-
<br>ing astrocyte activation have been reported, including the suppres-
<br>sion of astrocyte proliferation (Bush et al., 1999), the deletion of
<br>astrocyte intermediate filament proteins (Pekny et al., 1999; Lund-
<br>kvist et al., 2004), and the knock-down/inhibition of key inflamma-
<br>tory signaling pathways (Okada et al., 2006; Herrmann et al., 2008;
<br>Wanner et al., 2013). These manipulations have revealed many ap-
<br>parently protective functions of activated astrocytes after acute CNS
<br>trauma; for example, the formation of protective glial scars, support
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:324px; top:8095px; width:27px; height:10px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">suggest
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:7999px; width:332px; height:80px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">AAV-Gfa2-VIVIT protects against the loss of synaptic proteins. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Representative Western blots and mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SD
<br></span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:9px">Figure 6.
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">levels (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">D</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) for hippocampal synaptic proteins in the contralateral and ipsilateral hemispheres of rats treated with AAV-Gfa2-EGFP
<br>(CT) or AAV-Gfa2-VIVIT. Protein levels in </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">D</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">are from the ipsilateral hemisphere and are expressed as the percentage change from
<br>the contralateral hemisphere. The percentage change in the ipsilateral versus contralateral hemisphere of sham controls are also
<br>provided. Levels for PSD95 and GluR1 showed significant reductions in the ipsilateral hemisphere of AAV-Gfa2-EGFP rats, *</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.05 ipsilateral versus contralateral, Fisher’s PLSD test, but not in the ipsilateral hemisphere of VIVIT-treated rats. Although Syn1
<br>was not significantly reduced with injury, protein levels in the ipsilateral hemisphere were significantly increased by pretreatment
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">with AAV-Gfa2-VIVIT. *</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.05 ipsilateral versus contralateral, Fisher’s PLSD test, </span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫽ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">5– 6 rats per group.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:8093px; width:243px; height:208px;"><span style="font-family: ALPLNI+Minion-Bold; font-size:10px">AAV-Gfa2-VIVIT does not reduce glial activation after CCI,
<br>but does modulate astrocyte-related proteins involved in
<br>synaptic remodeling
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Our work, and work from others, has shown that the CN/NFAT
<br>pathway is an important regulator of the activated phenotypes of
<br>both astrocytes (Norris et al., 2005; Fernandez et al., 2007; Sama
<br>et al., 2008; Serrano-Pe´rez et al., 2011; Furman et al., 2012) and
<br>microglia (Kataoka et al., 2009; Nagamoto-Combs and Combs,
<br>2010; Shiratori et al., 2010). We previously showed that AAV-
<br>Gfa2-VIVIT protects synaptic function in a chronic, progressive
<br>disease model (APP/PS1 mice) in parallel with reductions in
<br>GFAP and Iba1 (a microglial protein). As shown in Figure 7,
<br></span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">A</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">–</span><span style="font-family: ALPIDL+Minion-Italic; font-size:10px">D</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">, we performed similar measures on GFAP and Iba1 protein
<br>levels in the rat CCI model. Although we did observe significant
<br>injury-related elevations for both proteins, consistent with ro-
<br>bust glial activation, neither protein marker was sensitive to
<br>AAV-Gfa2-VIVIT treatment. These results suggest that the syn-
<br>aptoprotective effects of AAV-Gfa2-VIVIT after acute injury do
<br>not require a reduction in glial activation.
<br></span></div><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:-9px; top:7886px; width:549px; height:452px;"><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:44px; top:7755px; width:328px; height:234px;"></div></div><span style="position:absolute; border: black 1px solid; left:42px; top:7643px; width:243px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:42px; top:7630px; width:243px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:42px; top:7718px; width:243px; height:0px;"></span>
<span style="position:absolute; border: gray 1px solid; left:0px; top:8380px; width:585px; height:783px;"></span>
<div style="position:absolute; top:8380px;"><a name="11">Page 11</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:8417px; width:140px; height:8px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">1512 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:355px; top:8414px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:8442px; width:243px; height:494px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">The present study sought to inhibit astrocyte activation in the rat
<br>CCI model by selectively inhibiting the CN/NFAT pathway in astro-
<br>cytes. In many cell types, CN/NFATs are key transcriptional regula-
<br>tors capable of driving striking changes in cellular phenotype
<br>(Crabtree and Olson, 2002; Horsley and Pavlath, 2002; Hogan et al.,
<br>2003; Wilkins and Molkentin, 2004; Hassoun et al., 2009). Although
<br>less attention has focused on CN/NFAT signaling in the CNS,
<br>mounting evidence suggests that CN/NFATs are associated with
<br>phenotype changes (i.e., activation) in astrocytes (Fernandez et al.,
<br>2007; Sama et al., 2008; Serrano-Pe´rez et al., 2011; Furman et al.,
<br>2012) and microglia (Kataoka et al., 2009; Nagamoto-Combs and
<br>Combs, 2010; Shiratori et al., 2010). In primary cultures, CN/NFAT
<br>induces numerous immune/inflammatory pathways, many of
<br>which are suppressed by the NFAT inhibitor VIVIT (Sama et al.,
<br>2008; Nagamoto-Combs and Combs, 2010). Previously, we showed
<br>that VIVIT expression in astrocytes over the course of 10–11 months
<br>using AAV-Gfa2 vectors was associated with a reduction in bio-
<br>chemical and morphological markers of glial activation in a mouse
<br>model (APP/PS1) of AD (Furman et al., 2012). Similar to cell culture
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">studies, the effects of AAV-Gfa2-VIVIT in APP/PS1 mice were ben-
<br>eficial in nature and included improved synaptic function and cog-
<br>nition, suggesting that astrocyte activation can exacerbate neural
<br>dysfunction, at least in the context of progressive amyloid pathology.
<br>Together, these studies provided seemingly strong rationale for
<br>using AAV-Gfa2-VIVIT to test the impact of activated astrocytes on
<br>neural function in an intact animal model of TBI. To our surprise,
<br>however, AAV-Gfa2-VIVIT had little to no effect on GFAP or Iba1
<br>levels in brain-injured rats. If anything, AAV-Gfa2-VIVIT precipi-
<br>tated an increase in Iba1 levels in ipsilateral hippocampus, consistent
<br>with greater microglial activation. This apparent discrepancy with
<br>earlier findings in APP/PS1 mice could indicate fundamental differ-
<br>ences in the activated glial phenotype(s) associated with acute injury
<br>versus progressive neuropathology (i.e., amyloid deposition). In-
<br>deed, there is strong evidence to suggest that multiple phenotypic
<br>characteristics of activated astrocytes, including transcriptional pro-
<br>file and proliferative capacity, can differ significantly depending on
<br>the nature of the insult and/or underlying pathology (Zamanian et
<br>al., 2012; Sirko et al., 2013). It is also possible that the relative contri-
<br>bution of astrocytes and CN/NFAT signaling to glial activation, and
<br>neuroinflammation in general, is greater in chronic disease condi-
<br>tions relative to acute injury. Regardless, the synaptoprotective ef-
<br>fects of AAV-Gfa2-VIVIT, in the face of robust glial activation,
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">suggests that the astrocytic CN/NFAT pathway influences neural
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">function through mechanisms that are independent of classic neu-
<br>roinflammatory signaling mediators.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:8948px; width:243px; height:186px;"><span style="font-family: ALPLNI+Minion-Bold; font-size:10px">Effects of AAV-Gfa2-VIVIT on synaptic function markers
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Although the impact of AAV-Gfa2-VIVIT on glial activation ap-
<br>peared markedly different in the rat CCI model compared with APP/
<br>PS1 mice, the beneficial effects of VIVIT treatment on synaptic
<br>function were highly similar. The large reduction in synaptic
<br>strength measured in ipsilateral slices from AAV-Gfa2-EGFP con-
<br>trol rats was essentially absent in AAV-Gfa2-VIVIT-treated rats.
<br>AAV-Gfa2-VIVIT also prevented the loss (or hastened the recovery)
<br>of several synaptic proteins and reduced susceptibility to LTD in
<br>injured hippocampus. Although the specific mechanisms linking as-
<br>trocytic CN/NFATs to impaired synaptic function remain unsettled,
<br>Western blots suggested a possibly important role for hevin, an
<br>astrocyte-secreted protein that regulates physical interactions be-
<br>tween cells and the extracellular matrix in a variety of tissues (Sulli-
<br>van et al., 2004; Jones and Bouvier, 2014). The dynamic interactions
<br>between hevin and SPARC have been proposed as a critical mecha-
<br>nism for fine tuning synaptic networks during development
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:8887px; width:243px; height:129px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:9px">Figure 7.
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">AAV-Gfa2-VIVIT does not alter GFAP or Iba1 levels, but causes an increase in hevin
<br></span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">levels. Representative Western blots (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">A</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">C</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) and mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SD. GFAP and Iba1 protein levels (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">B</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">D</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">)
<br>in the contralateral and ipsilateral hippocampus of AAV-treated rats at 7 d after CCI. Note that
<br>both glial markers showed a significant increase in the hippocampus of the ipsilateral hemi-
<br>sphere, but were not significantly altered by pretreatment with AAV-Gfa2-VIVIT. #</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.001
<br>ipsilateral versus contralateral, Fisher’s PLSD. </span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫽ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">5– 6 rats, group. </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">E</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">–</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">H</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, Representative West-
<br>ern blots (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">E</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">G</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) and mean </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫾ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">SD SPARC and hevin protein levels (</span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">F</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">, </span><span style="font-family: AMBAPK+MyriadMM-BoldCondensedItalic; font-size:9px">H</span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">) in the contralateral and
<br>ipsilateral hippocampus of AAV-treated rats at 7 d after CCI. No virus or injury-dependent effects
<br>were observed for SPARC. In contrast, hevin was sensitive to both injury and AAV treatment. In
<br>both AAV groups, hevin was elevated in the ipsilateral relative to the contralateral hemisphere.
<br>Overall hevin levels were greater in the VIVIT-treated group regardless of hemisphere, but were
<br>highest in the injured hemisphere. *</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.05; #</span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">p </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⬍ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">0.001 ipsilateral versus contralateral,
<br>Fisher’s LSD, </span><span style="font-family: AMBBHG+MyriadMM-RegularCondensedIt; font-size:9px">n </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫽ </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:9px">5– 6 rats.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:9036px; width:243px; height:98px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">of the blood–brain barrier, myelin preservation, and/or the protec-
<br>tion of neuronal viability. In contrast, other reports have suggested
<br>that activated astrocytes have a detrimental impact on nervous tis-
<br>sue. For instance, suppression of astrocyte activation via the com-
<br>bined knock-down of GFAP and vimentin led to improved synaptic
<br>recovery in the outer molecular layer of the dentate gyrus after an
<br>entorhinal cortex lesion (Wilhelmsson et al., 2004). These observa-
<br>tions highlight the complexity and possibly the heterogeneity of as-
<br>trocyte activation during injury and disease.
<br></span></div><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:-9px; top:8665px; width:548px; height:506px;"><div style="position:absolute; border: figure 1px solid; writing-mode:False; left:45px; top:8444px; width:236px; height:433px;"></div></div><span style="position:absolute; border: gray 1px solid; left:0px; top:9213px; width:585px; height:783px;"></span>
<div style="position:absolute; top:9213px;"><a name="12">Page 12</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:9247px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:403px; top:9250px; width:140px; height:8px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">• 1513
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:9275px; width:243px; height:109px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">(Kucukdereli et al., 2011) and possibly after neural injury (Blakely et
<br>al., 2015). Similar to previous reports (Lively and Brown, 2008;
<br>Lively et al., 2011), we observed an injury-related increase in hevin
<br>levels in the rat CCI model. Perhaps more remarkably, hevin expres-
<br>sion was strongly induced by VIVIT, an effect that was potentiated
<br>with injury. It is possible that elevated NFAT activity in activated
<br>astrocytes keeps hevin expression somewhat in check through direct
<br>transcriptional suppression. Conversely, NFATs may limit the activ-
<br>ity/expression of other transcription factors that stimulate hevin
<br>induction.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:9385px; width:243px; height:285px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">In addition to hevin, there are many other possible astrocyte-
<br>based mechanisms that could link CN/NFAT signaling to synaptic
<br>function. For instance, complement components such as C3
<br>are associated with astrocyte activation (Tomimoto et al., 1997; Car-
<br>dinaux et al., 2000) and synapse loss (Stevens et al., 2007) and are
<br>sensitive to CN activity (Norris et al., 2005). Astrocytes also protect
<br>neuronal viability and fine tune synaptic transmission by removing
<br>excess glutamate from the extracellular milieu (Sattler and Roth-
<br>stein, 2006), a process that is protected by VIVIT in primary culture
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">models of neuroinflammation and amyloid toxicity (Sama et al.,
<br>2008; Abdul et al., 2009). Alternatively, astrocytic CN/NFAT signal-
<br>ing may stimulate the release of excitotoxic factors that disrupt
<br>neuronal Ca </span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:6px">⫹ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">dysregulation, which in turn lead to synapse dys</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">-
<br>function, particularly in regard to the expression of synaptic plastic-
<br>ity. LTD, for example, is normally absent in hippocampal slices from
<br>healthy adult rodents when the bath Ca </span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:6px">⫹</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">/Mg </span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:6px">⫹ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">concentrations are
<br>at a one-to-one ratio (O’Dell and Kandel, 1994; Norris et al., 1996;
<br>Vouimba et al., 2000; Foster and Kumar, 2007; Shankar et al., 2008;
<br>Dumas, 2012), but is much easier to induce in slices under condi-
<br>tions that promote Ca </span><span style="font-family: ALPGDF+Minion-Regular; font-size:6px">2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:6px">⫹ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">dysregulation such as aging, injury, and
<br>elevated amyloid levels (Norris et al., 1996; Vouimba et al., 2000;
<br>Foster and Kumar, 2007; Shankar et al., 2008; Li et al., 2009; Ma et al.,
<br>2012; Sama et al., 2012; Norris et al., 2016). Clearly, future studies
<br>will be needed to fully characterize NFAT interactions with hevin
<br>and multiple other astrocyte-based signaling mechanisms and their
<br>roles in synaptic recovery and repair.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:9682px; width:243px; height:285px;"><span style="font-family: ALPLNI+Minion-Bold; font-size:10px">NFAT isoforms and astrocyte signaling after CCI
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Similar to peripheral tissues, changes in glial signaling may hinge
<br>upon the expression of specific NFAT isoforms. NFATs 1, 2, and 4
<br>have each been implicated in the production of proinflammatory
<br>cytokines and chemokines in glial cells (Canellada et al., 2008; Perez-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Ortiz et al., 2008; Nagamoto-Combs and Combs, 2010; Neria et al.,
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">2013). Previously, we observed elevated levels of NFAT1 activation
<br>in astrocytes in human hippocampus at early stages of cognitive
<br>decline associated with AD (Abdul et al., 2009). Other groups have
<br>observed an increase in the localization of NFAT4 to hippocampal
<br>astrocytes, particularly after acute injury (Serrano-Pe´rez et al., 2011;
<br>Neria et al., 2013; Yan et al., 2014). Consistent with these reports, the
<br>present study found that NFAT–DNA interactions were increased in
<br>the hippocampus after unilateral CCI and attributable largely to the
<br>activities of NFATs 1 and 4. However, confocal micrographs showed
<br>that the expression of NFAT4 is far more selective for astrocytes.
<br>Unlike our work on human tissue, we found little to no evidence
<br>linking NFAT 1 to activated astrocytes in brain-injured rats. It’s pos-
<br>sible that NFAT1 is primarily associated with microglia and/or infil-
<br>trating immune cells in rodents or that its activity is strongly
<br>stimulated in astrocytes at earlier time points after injury, but then
<br>recedes with time. There may also be significant differences in the
<br>expression and function of different NFAT isoforms across rodents
<br>and humans. Further work using biochemical and fluorescence mi-
<br>croscopy techniques will be needed to evaluate these possibilities and
<br>to identify the cell types that express NFAT1 after injury.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:9275px; width:243px; height:285px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Injury-dependent elevations in activity, coupled with intense
<br>astrocyte-specific expression, suggest that NFAT4 is the most likely
<br>target of VIVIT’s synaptoprotective effects. Interestingly, the colo-
<br>calization of NFAT4 with GFAP exhibited considerable heterogene-
<br>ity across the hippocampus, characterized by extensive labeling in
<br>CA1 and the dentate and little labeling in CA3. Within the CA1 and
<br>dentate regions, NFAT4 was found in the dendritic–axonal layers,
<br>but was largely excluded from the cell body layers. The dendrite/
<br>axonal layers of CA1 and the dentate are where much of the loss (and
<br>subsequent recovery) of synapses take place in the hippocampus
<br>after unilateral CCI (Scheff et al., 2005; Winston et al., 2013), exactly
<br>where NFAT4 upregulation appeared in the present study. These
<br>results suggest that astrocytic NFAT4 is intimately associated with
<br>excitatory synaptic contacts (which are largely excluded from neu-
<br>ronal cell body layers), where it appears to robustly respond to
<br>changes in the functional status and/or viability of these connections.
<br>Although our findings suggest that NFAT4 may negatively affect
<br>synaptic recovery after injury by limiting the expression of hevin (or
<br>other protective factors), the role of NFAT4 in synaptic function
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">during nondisease/injury conditions is unknown. Previously, we
<br>found few alterations in basal synaptic strength and LTP in wild-type
<br>mice treated for </span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:10px">⬎</span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">10 months with AAV-Gfa2-VIVIT, suggesting
<br>that astrocytic NFAT4 does not dramatically alter fundamental
<br>mechanisms of synaptic transmission in adult animals. Nonetheless,
<br>further work will be necessary to clarify the impact of NFAT4 on
<br>synapses under both normal and pathological conditions.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:9572px; width:243px; height:120px;"><span style="font-family: ALPLNI+Minion-Bold; font-size:10px">Conclusion
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:10px">Activated astrocytes have been shown to play both protective and
<br>deleterious roles in acute injury and chronic neurodegenerative dis-
<br>ease. Along with several other earlier reports, the present study sug-
<br>gests that
<br>the deleterious actions of activated astrocytes—in
<br>particular the synaptotoxic effects of astrocytes—may hinge upon
<br>the functional status of the CN/NFAT pathway. The results of this
<br>study may offer important clues into how astrocytes affect neuronal
<br>circuit rewiring after acute injury and establish astrocyte-based sig-
<br>naling pathways as possible targets for preserving or improving neu-
<br>ral function after acute head trauma.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:9707px; width:243px; height:59px;"><span style="font-family: ALPEID+MinionMM-BoldCondensed; font-size:13px">References
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM,
<br>Patel ES, Baig I, Murphy MP, LeVine H 3rd, Kraner SD, Norris CM
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">(2009) Cognitive decline in Alzheimer’s disease is associated with selec-
<br>tive changes in calcineurin/NFAT signaling. J Neurosci 29:12957–12969.
<br>CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:9768px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Albrecht D, Lo´ pez-Murcia FJ, Pe´rez-Gonza´lez AP, Lichtner G, Solsona C,
<br>Llobet A (2012) SPARC prevents maturation of cholinergic presynaptic
<br>terminals. Mol Cell Neurosci 49:364 –374. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:9796px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Anderson MA, Ao Y, Sofroniew MV (2014) Heterogeneity of reactive astro-
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:312px; top:9806px; width:158px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">cytes. Neurosci Lett 565:23–29. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:9815px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Ansari MA, Roberts KN, Scheff SW (2013) Dose- and time-dependent neu-
<br>roprotective effects of Pycnogenol following traumatic brain injury.
<br>J Neurotrauma 30:1542–1549. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:9844px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Aramburu J, Yaffe MB, Lo´pez-Rodríguez C, Cantley LC, Hogan PG, Rao A
<br>(1999) Affinity-driven peptide selection of an NFAT inhibitor more selective
<br>than cyclosporin A. Science 285:2129–2133. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:9872px; width:243px; height:36px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Baldwin SA, Gibson T, Callihan CT, Sullivan PG, Palmer E, Scheff SW (1997)
<br>Neuronal cell loss in the CA3 subfield of the hippocampus following
<br>cortical contusion utilizing the optical disector method for cell counting.
<br>J Neurotrauma 14:385–398. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:9910px; width:243px; height:36px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Bales JW, Ma X, Yan HQ, Jenkins LW, Dixon CE (2010) Expression of
<br>protein phosphatase 2B (calcineurin) subunit A isoforms in rat hip-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">pocampus after traumatic brain injury. J Neurotrauma 27:109 –120.
<br>CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:9948px; width:243px; height:17px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Blakely PK, Hussain S, Carlin LE, Irani DN (2015) Astrocyte matricellular
<br>proteins that control excitatory synaptogenesis are regulated by inflam-
<br></span></div><span style="position:absolute; border: gray 1px solid; left:0px; top:10046px; width:585px; height:783px;"></span>
<div style="position:absolute; top:10046px;"><a name="13">Page 13</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10083px; width:140px; height:8px;"><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">1514 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:355px; top:10080px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:54px; top:10107px; width:231px; height:28px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">matory cytokines and correlate with paralysis severity during experimen-
<br>tal autoimmune encephalomyelitis. Front Neurosci 9:344. CrossRef
<br>Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10137px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Burda JE, Bernstein AM, Sofroniew MV (2015) Astrocyte roles in traumatic
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:54px; top:10147px; width:220px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">brain injury. Exp Neurol pii: S0014-4886(15)00089-8. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10156px; width:243px; height:47px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen
<br>CN, Mucke L, Johnson MH, Sofroniew MV (1999) Leukocyte infiltra-
<br>tion, neuronal degeneration, and neurite outgrowth after ablation of scar-
<br>forming, reactive astrocytes in adult transgenic mice. Neuron 23:297–308.
<br>CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10205px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Canellada A, Ramirez BG, Minami T, Redondo JM, Cano E (2008) Calci-
<br>um/calcineurin signaling in primary cortical astrocyte cultures: Rcan1– 4
<br>and cyclooxygenase-2 as NFAT target genes. Glia 56:709 –722. CrossRef
<br>Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10244px; width:243px; height:47px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Caraveo G, Auluck PK, Whitesell L, Chung CY, Baru V, Mosharov EV, Yan X,
<br>Ben-Johny M, Soste M, Picotti P, Kim H, Caldwell KA, Caldwell GA,
<br>Sulzer D, Yue DT, Lindquist S (2014) Calcineurin determines toxic ver-
<br>sus beneficial responses to alpha-synuclein. Proc Natl Acad Sci U S A
<br>111:E3544 –3552. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10293px; width:243px; height:28px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Cardinaux JR, Allaman I, Magistretti PJ (2000) Pro-inflammatory cytokines
<br>induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes.
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Glia 29:91–97. Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10322px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Celsi F, Svedberg M, Unger C, Cotman CW, Carrì MT, Ottersen OP, Nord-
<br>berg A, Torp R (2007) Beta-amyloid causes downregulation of calcineu-
<br>rin in neurons through induction of oxidative stress. Neurobiol Dis 26:
<br>342–352. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10361px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Crabtree GR, Olson EN (2002) NFAT signaling: choreographing the social
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:54px; top:10371px; width:157px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">lives of cells. Cell 109:S67–S79. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10381px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">de Leeuw B, Su M, ter Horst M, Iwata S, Rodijk M, Hoeben RC, Messing A, Smitt
<br>PS, Brenner M (2006) Increased glia-specific transgene expression with glial
<br>fibrillary acidic protein promoters containing multiple enhancer elements.
<br>J Neurosci Res 83:744–753. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10420px; width:243px; height:28px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Dumas TC (2012) Postnatal alterations in induction threshold and expression
<br>magnitude of long-term potentiation and long-term depression at hip-
<br>pocampal synapses. Hippocampus 22:188–199. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10449px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Fernandez AM, Fernandez S, Carrero P, Garcia-Garcia M, Torres-Aleman I
<br>(2007) Calcineurin in reactive astrocytes plays a key role in the interplay
<br>between proinflammatory and anti-inflammatory signals. J Neurosci 27:
<br>8745– 8756. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10488px; width:243px; height:28px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Foster TC, Kumar A (2007) Susceptibility to induction of long-term depres-
<br>sion is associated with impaired memory in aged Fischer 344 rats. Neuro-
<br>biol Learn Mem 87:522–535. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10518px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Furman JL, Norris CM (2014) Calcineurin and glial signaling: neuroinflam-
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:54px; top:10527px; width:219px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">mation and beyond. J Neuroinflammation 11:158. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10537px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD,
<br>Van Eldik LJ, Norris CM (2012) Targeting astrocytes ameliorates neu-
<br>rologic changes in a mouse model of Alzheimer’s disease. J Neurosci
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">32:16129 –16140. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10576px; width:243px; height:28px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Gilmer LK, Roberts KN, Joy K, Sullivan PG, Scheff SW (2009) Early mito-
<br>chondrial dysfunction after cortical contusion injury. J Neurotrauma 26:
<br>1271–1280. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10605px; width:243px; height:47px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Hashimoto T, Kawamata T, Saito N, Sasaki M, Nakai M, Niu S, Taniguchi T,
<br>Terashima A, Yasuda M, Maeda K, Tanaka C (1998) Isoform-specific
<br>redistribution of calcineurin A alpha and A beta in the hippocampal CA1
<br>region of gerbils after transient ischemia. J Neurochem 70:1289 –1298.
<br>Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10654px; width:243px; height:47px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Hassoun PM, Mouthon L, Barbera` JA, Eddahibi S, Flores SC, Grimminger F,
<br>Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Ra-
<br>binovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX, Humbert
<br>M (2009) Inflammation, growth factors, and pulmonary vascular re-
<br>modeling. J Am Coll Cardiol 54:S10 –S19. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10703px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Herrmann JE, Imura T, Song B, Qi J, Ao Y, Nguyen TK, Korsak RA, Takeda K,
<br>Akira S, Sofroniew MV (2008) STAT3 is a critical regulator of astroglio-
<br>sis and scar formation after spinal cord injury. J Neurosci 28:7231–7243.
<br>CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10742px; width:243px; height:28px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM (2001)
<br>Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">directed gene transfer. J Virol 75:6199–6203. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10771px; width:243px; height:28px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Hogan PG, Chen L, Nardone J, Rao A (2003) Transcriptional regulation by
<br>calcium, calcineurin, and NFAT. Genes Dev 17:2205–2232. CrossRef
<br>Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10107px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Horsley V, Pavlath GK (2002) NFAT: ubiquitous regulator of cell differen-
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:312px; top:10117px; width:210px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">tiation and adaptation. J Cell Biol 156:771–774. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10127px; width:243px; height:47px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Huang W, Fileta JB, Dobberfuhl A, Filippopolous T, Guo Y, Kwon G,
<br>Grosskreutz CL (2005) Calcineurin cleavage is triggered by elevated in-
<br>traocular pressure, and calcineurin inhibition blocks retinal ganglion cell
<br>death in experimental glaucoma. Proc Natl Acad Sci U S A 102:12242–
<br>12247. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10175px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Jones EV, Bouvier DS (2014) Astrocyte-secreted matricellular proteins in
<br>CNS remodelling during development and disease. Neural Plast 2014:
<br>321209. Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10204px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Jones EV, Bernardinelli Y, Tse YC, Chierzi S, Wong TP, Murai KK (2011)
<br>Astrocytes control glutamate receptor levels at developing synapses
<br>through SPARC-beta-integrin interactions. J Neurosci 31:4154 – 4165.
<br>CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10242px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Kataoka A, Tozaki-Saitoh H, Koga Y, Tsuda M, Inoue K (2009) Activation of
<br>P2X7 receptors induces CCL3 production in microglial cells through tran-
<br>scription factor NFAT. J Neurochem 108:115–125. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10271px; width:243px; height:46px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Kucukdereli H, Allen NJ, Lee AT, Feng A, Ozlu MI, Conatser LM,
<br>Chakraborty C, Workman G, Weaver M, Sage EH, Barres BA, Eroglu C
<br>(2011) Control of excitatory CNS synaptogenesis by astrocyte-secreted
<br>proteins Hevin and SPARC. Proc Natl Acad Sci U S A 108:E440 –E449.
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10319px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Lee Y, Messing A, Su M, Brenner M (2008) GFAP promoter elements re-
<br>quired for region-specific and astrocyte-specific expression. Glia 56:
<br>481– 493. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10348px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009)
<br>Soluble oligomers of amyloid Beta protein facilitate hippocampal long-
<br>term depression by disrupting neuronal glutamate uptake. Neuron 62:
<br>788 – 801. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10387px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Liu F, Grundke-Iqbal I, Iqbal K, Oda Y, Tomizawa K, Gong CX (2005)
<br>Truncation and activation of calcineurin A by calpain I in Alzheimer
<br>disease brain. J Biol Chem 280:37755–37762. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10416px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Lively S, Brown IR (2008) Localization of the extracellular matrix protein
<br>SC1 coincides with synaptogenesis during rat postnatal development.
<br>Neurochem Res 33:1692–1700. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10444px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Lively S, Moxon-Emre I, Schlichter LC (2011) SC1/hevin and reactive glio-
<br>sis after transient ischemic stroke in young and aged rats. J Neuropathol
<br>Exp Neurol 70:913–929. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10473px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Lundkvist A, Reichenbach A, Betsholtz C, Carmeliet P, Wolburg H, Pekny M
<br>(2004) Under stress, the absence of intermediate filaments from Muller
<br>cells in the retina has structural and functional consequences. J Cell Sci
<br>117:3481–3488. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10512px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E (2012) Glucagon-like
<br>peptide-1 cleavage product GLP-1(9 –36) amide rescues synaptic plastic-
<br>ity and memory deficits in Alzheimer’s disease model mice. J Neurosci
<br>32:13701–13708. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10550px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Malinow R, Miller JP (1986) Postsynaptic hyperpolarization during condi-
<br>tioning reversibly blocks induction of long-term potentiation. Nature
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">320:529 –530. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10579px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Mathis DM, Furman JL, Norris CM (2011) Preparation of acute hippocam-
<br>pal slices from rats and transgenic mice for the study of synaptic altera-
<br>tions during aging and amyloid pathology. J Vis Exp 49: pii: 2330.
<br>CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10618px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Mohmmad Abdul H, Baig I, Levine H 3rd, Guttmann RP, Norris CM (2011)
<br>Proteolysis of calcineurin is increased in human hippocampus during
<br>mild cognitive impairment and is stimulated by oligomeric Abeta in pri-
<br>mary cell culture. Aging Cell 10:103–113. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10656px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Mulkey RM, Malenka RC (1992) Mechanisms underlying induction of ho-
<br>mosynaptic long-term depression in area CA1 of the hippocampus. Neu-
<br>ron 9:967–975. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10685px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Nagamoto-Combs K, Combs CK (2010) Microglial phenotype is regulated
<br>by activity of the transcription factor, NFAT (nuclear factor of activated T
<br>cells). J Neurosci 30:9641–9646. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10714px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Neal JW, Clipstone NA (2001) Glycogen synthase kinase-3 inhibits the
<br>DNA binding activity of NFATc. J Biol Chem 276:3666 –3673. CrossRef
<br>Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10743px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Neria F, del Carmen Serrano-Pe´rez M, Velasco P, Urso K, Tranque P, Cano E
<br>(2013) NFATc3 promotes Ca(2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫹</span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">)-dependent MMP3 expression in as-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">troglial cells. Glia 61:1052–1066. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10772px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Nguyen T, Di Giovanni S (2008) NFAT signaling in neural development and
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:312px; top:10781px; width:193px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">axon growth. Int J Dev Neurosci 26:141–145. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10791px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Norris CM (2014) Calpain interactions with the protein phosphatase cal-
<br></span></div><span style="position:absolute; border: gray 1px solid; left:0px; top:10879px; width:585px; height:783px;"></span>
<div style="position:absolute; top:10879px;"><a name="14">Page 14</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10913px; width:188px; height:11px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Furman, Sompol et al. </span><span style="font-family: ALPJEP+Symbol; font-size:10px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">Astrocytic NFAT Signaling and Traumatic Brain Injury
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:403px; top:10916px; width:140px; height:8px;"><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">J. Neurosci., February 3, 2016 </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:7px">• </span><span style="font-family: ALPGJN+MyriadMM-RegularCondensed; font-size:8px">36(5):1502–1515 </span><span style="font-family: ALPGLI+MyriadMM-BoldCondensed; font-size:8px">• 1515
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:54px; top:10940px; width:231px; height:17px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">cineurin in neurodegeneration. Advances in Biochemistry in Health and
<br>Disease 8:17– 45.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10959px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Norris CM, Scheff SW (2009) Recovery of afferent function and synaptic
<br>strength in hippocampal CA1 following traumatic brain injury. J Neu-
<br>rotrauma 26:2269 –2278. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:10988px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Norris CM, Korol DL, Foster TC (1996) Increased susceptibility to induc-
<br>tion of long-term depression and long- term potentiation reversal during
<br>aging. J Neurosci 16:5382–5392. Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11016px; width:243px; height:36px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Norris CM, Kadish I, Blalock EM, Chen KC, Thibault V, Porter NM, Land-
<br>field PW, Kraner SD (2005) Calcineurin triggers reactive/inflammatory
<br>processes in astrocytes and is upregulated in aging and Alzheimer’s mod-
<br>els. J Neurosci 25:4649 – 4658. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11054px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Norris CM, Sompol P, Roberts KN, Ansari M, Scheff SW (2016) Pycnogenol
<br>protects CA3–CA1 synaptic function in a rat model of traumatic brain
<br>injury. Exp Neurol 276:5–12. Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11083px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">O’Dell TJ, Kandel ER (1994) Low-frequency stimulation erases LTP
<br>through an NMDA receptor-mediated activation of protein phospha-
<br>tases. Learn Mem 1:129 –139. Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11111px; width:243px; height:36px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Okada S, Nakamura M, Katoh H, Miyao T, Shimazaki T, Ishii K, Yamane J,
<br>Yoshimura A, Iwamoto Y, Toyama Y, Okano H (2006) Conditional ab-
<br>lation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after
<br>spinal cord injury. Nat Med 12:829 – 834. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11149px; width:243px; height:36px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG,
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Stout RF Jr, Spray DC, Reichenbach A, Pannicke T, Pekny M, Pekna M,
<br>Zorec R, Verkhratsky A (2012) Glial cells in (patho)physiology. J Neu-
<br>rochem 121:4 –27. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11187px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Pekny M, Nilsson M (2005) Astrocyte activation and reactive gliosis. Glia
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:54px; top:11197px; width:98px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">50:427– 434. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11206px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Pekny M, Pekna M (2014) Astrocyte reactivity and reactive astrogliosis:
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:54px; top:11216px; width:204px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">costs and benefits. Physiol Rev 94:1077–1098. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11225px; width:243px; height:36px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Pekny M, Johansson CB, Eliasson C, Stakeberg J, Walle´n A, Perlmann T,
<br>Lendahl U, Betsholtz C, Berthold CH, Frisen J (1999) Abnormal reac-
<br>tion to central nervous system injury in mice lacking glial fibrillary acidic
<br>protein and vimentin. J Cell Biol 145:503–514. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11263px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Pekny M, Wilhelmsson U, Pekna M (2014) The dual role of astrocyte activation
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:54px; top:11273px; width:194px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">and reactive gliosis. Neurosci Lett 565:30–38. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11282px; width:243px; height:36px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Pe´rez-Ortiz JM, Serrano-Pe´rez MC, Pastor MD, Martín ED, Calvo S, Rinco´ n
<br>M, Tranque P (2008) Mechanical
<br>lesion activates newly identified
<br>NFATc1 in primary astrocytes: implication of ATP and purinergic recep-
<br>tors. Eur J Neurosci 27:2453–2465. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11320px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Rosenkranz K, May C, Meier C, Marcus K (2012) Proteomic analysis of
<br>alterations induced by perinatal hypoxic-ischemic brain injury. J Pro-
<br>teome Res 11:5794 –5803. Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11349px; width:243px; height:36px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Sama DM, Mohmmad Abdul H, Furman JL, Artiushin IA, Szymkowski DE,
<br>Scheff SW, Norris CM (2012) Inhibition of soluble tumor necrosis fac-
<br>tor ameliorates synaptic alterations and Ca2</span><span style="font-family: ALPHMO+Universal-GreekwithMathPi; font-size:8px">⫹ </span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">dysregulation in aged rats.
<br>PLoS One 7:e38170. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11387px; width:243px; height:36px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Sama MA, Mathis DM, Furman JL, Abdul HM, Artiushin IA, Kraner SD,
<br>Norris CM (2008) Interleukin-1beta-dependent signaling between as-
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">trocytes and neurons depends critically on astrocytic calcineurin/NFAT
<br>activity. J Biol Chem 283:21953–21964. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11425px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Sattler R, Rothstein JD (2006) Regulation and dysregulation of glutamate
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:54px; top:11434px; width:219px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">transporters. Handb Exp Pharmacol 175:277–303. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11444px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Scheff SW, Price DA, Hicks RR, Baldwin SA, Robinson S, Brackney C (2005)
<br>Synaptogenesis in the hippocampal CA1 field following traumatic brain
<br>injury. J Neurotrauma 22:719 –732. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11472px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Scheff SW, Ansari MA, Roberts KN (2013) Neuroprotective effect of Pyc-
<br>nogenol(R) following traumatic brain injury. Exp Neurol 239:183–191.
<br>CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11501px; width:243px; height:36px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Serrano-Pe´rez MC, Martin ED, Vaquero CF, Azcoitia I, Calvo S, Cano E,
<br>Tranque P (2011) Response of transcription factor NFATc3 to excito-
<br>toxic and traumatic brain insults: identification of a subpopulation of
<br>reactive astrocytes. Glia 59:94 –107. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11539px; width:243px; height:46px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I,
<br>Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM,
<br>Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated di-
<br>rectly from Alzheimer’s brains impair synaptic plasticity and memory.
<br>Nat Med 14:837– 842. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:42px; top:11586px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Shioda N, Moriguchi S, Shirasaki Y, Fukunaga K (2006) Generation of con-
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:312px; top:10940px; width:231px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">stitutively active calcineurin by calpain contributes to delayed neuronal
<br>death following mouse brain ischemia. J Neurochem 98:310 –320.
<br>CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:10969px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Shiratori M, Tozaki-Saitoh H, Yoshitake M, Tsuda M, Inoue K (2010) P2X7
<br>receptor activation induces CXCL2 production in microglia through
<br>NFAT and PKC/MAPK pathways. J Neurochem 114:810 – 819. CrossRef
<br>Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11008px; width:243px; height:56px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Sirko S, Behrendt G, Johansson PA, Tripathi P, Costa M, Bek S, Heinrich C,
<br>Tiedt S, Colak D, Dichgans M, Fischer IR, Plesnila N, Staufenbiel M,
<br>Haass C, Snapyan M, Saghatelyan A, Tsai LH, Fischer A, Grobe K, Dimou
<br>L, Go¨tz M (2013) Reactive glia in the injured brain acquire stem cell
<br>properties in response to sonic hedgehog [corrected]. Cell Stem Cell 12:
<br>426 – 439. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11066px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:312px; top:11075px; width:205px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">scar formation. Trends Neurosci 32:638 – 647. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11085px; width:243px; height:47px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N,
<br>Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM,
<br>Lambris JD, Smith SJ, John SW, Barres BA (2007) The classical comple-
<br>ment cascade mediates CNS synapse elimination. Cell 131:1164 –1178.
<br>CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11133px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Sullivan MM, Sage EH (2004) Hevin/SC1, a matricellular glycoprotein and
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">potential tumor-suppressor of the SPARC/BM-40/Osteonectin family.
<br></span><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Int J Biochem Cell Biol 36:991–996. Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11162px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Tomimoto H, Akiguchi I, Wakita H, Suenaga T, Nakamura S, Kimura J
<br>(1997) Regressive changes of astroglia in white matter lesions in cerebro-
<br>vascular disease and Alzheimer’s disease patients. Acta Neuropathol 94:
<br>146 –152. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11201px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Vihma H, Pruunsild P, Timmusk T (2008) Alternative splicing and expres-
<br>sion of human and mouse NFAT genes. Genomics 92:279 –291. CrossRef
<br>Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11230px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Vouimba RM, Foy MR, Foy JG, Thompson RF (2000) 17beta-estradiol sup-
<br>presses expression of long-term depression in aged rats. Brain Res Bull
<br>53:783–787. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11259px; width:243px; height:47px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Wanner IB, Anderson MA, Song B, Levine J, Fernandez A, Gray-Thompson
<br>Z, Ao Y, Sofroniew MV (2013) Glial scar borders are formed by newly
<br>proliferated, elongated astrocytes that interact to corral inflammatory and
<br>fibrotic cells via STAT3-dependent mechanisms after spinal cord injury.
<br>J Neurosci 33:12870 –12886. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11307px; width:243px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Wigstrom H, Gustafsson B (1986) Postsynaptic control of hippocampal
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:312px; top:11317px; width:199px; height:8px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">long-term potentiation. J Physiol (Paris) 81:228 –236. Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11326px; width:243px; height:47px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Wilhelmsson U, Li L, Pekna M, Berthold CH, Blom S, Eliasson C, Renner O,
<br>Bushong E, Ellisman M, Morgan TE, Pekny M (2004) Absence of glial
<br>fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic
<br>processes and improves post-traumatic regeneration. J Neurosci 24:
<br>5016 –5021. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11374px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Wilkins BJ, Molkentin JD (2004) Calcium-calcineurin signaling in the reg-
<br>ulation of cardiac hypertrophy. Biochem Biophys Res Commun 322:
<br>1178 –1191. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11403px; width:243px; height:47px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Winston CN, Chellappa D, Wilkins T, Barton DJ, Washington PM, Loane DJ,
<br>Zapple DN, Burns MP (2013) Controlled cortical impact results in an
<br>extensive loss of dendritic spines that is not mediated by injury-induced
<br>amyloid-beta accumulation. J Neurotrauma 30:1966 –1972. CrossRef
<br>Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11452px; width:243px; height:47px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, Spires-Jones
<br>T, Xie H, Arbel-Ornath M, Grosskreutz CL, Bacskai BJ, Hyman BT (2010)
<br>Amyloid beta induces the morphological neurodegenerative triad of spine
<br>loss, dendritic simplification, and neuritic dystrophies through calcineurin
<br>activation. J Neurosci 30:2636–2649. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11500px; width:243px; height:37px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Yan HQ, Shin SS, Ma X, Li Y, Dixon CE (2014) Differential effect of trau-
<br>matic brain injury on the nuclear factor of activated T Cells C3 and C4
<br>isoforms in the rat hippocampus. Brain Res 1548:63–72. CrossRef
<br>Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11538px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Yu H, van Berkel TJ, Biessen EA (2007) Therapeutic potential of VIVIT, a se-
<br>lective peptide inhibitor of nuclear factor of activated T cells, in cardiovascu-
<br>lar disorders. Cardiovasc Drug Rev 25:175–187. CrossRef Medline
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:300px; top:11567px; width:243px; height:27px;"><span style="font-family: ALPGDF+Minion-Regular; font-size:8px">Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA (2012)
<br>Genomic analysis of reactive astrogliosis. J Neurosci 32:6391– 6410.
<br>CrossRef Medline
<br></span></div>